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Résumé 
La codéine et l'oxycodone sont des opioïdes utilisés pour soulager la douleur. Le succès du 
traitement dépend du métabolisme par les enzymes CYP450. Selon les médicaments utilisés, 
l’altération de métabolisme peut entraîner de graves conséquences, y compris des modifications 
dans leurs profils d'efficacité, de sécurité et de toxicité. L'objectif de cette étude consistait à 
évaluer par HPLC-MS / MS (trappe ionique linéaire) l'effet de l'âge sur le métabolisme de 
l'enzyme CYP2D chez les rats. La codéine et l'oxycodone ainsi que leurs métabolites 
spécifiques, morphine (CYP2D), norcodeine (CYP3A), oxymorphone (CYP2D) et 
noroxycodone (CYP3A), ont été quantifiés en utilisant la méthode de dilution isotopique. Les 
fractions S9 de foie de rats (Sprague-Dawley) de sexe masculin âgés de 3, 6, 12 et 18 mois ont 
été préparées et les paramètres de Michaelis-Menten ont été déterminés pour les principales 
voies métaboliques. La vitesse maximale de la réaction enzymatique (Vmax) a montré une 
saturation rapide des sites actifs de CYP2D dans la fraction s9 de foie chez les rats âgés de 18 
mois. Les valeurs de Vmax observées pour la codéine chez les rats âgés de 3, 6 et 12 mois étaient 
respectivement de 0,327 ± 0,027, 0,355 ± 0,021 et 0,273 ± 0,028. Concernant l'oxycodone, les 
valeurs étaient de 0,690 ± 0,096, 0,499 ± 0,087, 0,153 ± 0,01 respectivement. Cependant, la 
valeur de Vmax chez les rats âgés de 18 mois était de 0,092 ± 0,003 pour la codéine et de 0,153 ± 
0,01 pour l’oxycodone. Vraisemblablement, la valeur de Vmax affecte de manière significative (P 
≤ 0,05) la clairance enzymatique de ces médicaments (CLuint = Vmax / Km). Les résultats de cette 
étude suggèrent que l’enzyme CYP2D subit un changement conformationnel avec l'âge, 
particulièrement chez les rats âgés de 18 mois. Ce changement conformationnel conduit à une 
diminution significative du taux de formation des métabolites opioïdes actifs, ce qui entraine une 
diminution de la clairance enzymatique de ces médicaments. En conclusion, cette étude suggère 
une détérioration des CYP2D et CYP3A chez les rats vieillissants, ce qui affecte le métabolisme 
des médicaments.  
 Mots-clés: Opioïdes, vieillissement, métabolisme des médicaments, CYP450, CYP2D, CYP3A, 
spectrométrie de masse. 
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Abstract 
 
Codeine and oxycodone are opioids used in the treatment of pain. The outcome of the treatment 
is ultimately related to their metabolism by CYP450 enzymes. Depending on the drugs used, 
alterations in the metabolism of drugs by CYP450 enzymes can lead to severe consequences 
including alterations in their efficacy, safety and toxicity profiles. The objective of this study was 
to assess the effect of age on CYP2D enzyme metabolism in rats using HPLC-MS/MS (Linear 
Ion Trap). Codeine and oxycodone along with specific metabolites morphine (CYP2D), 
norcodeine (CYP3A), and oxymorphone (CYP2D), noroxycodone (CYP3A) were quantified 
using isotopic dilution method. Liver S9 fractions from 3, 6, 12, and 18 month-old male Sprague 
Dawley rats were prepared and Michaelis-Menten parameters were determined for their primary 
metabolic pathways. The derived maximum enzyme velocity (Vmax) suggested a rapid saturation 
of the CYP2D active sites in the liver S9 fractions of 18 month-old rats. The observed Vmax 
values for codeine in 3, 6 and 12 month-old rats respectively were 0.327 ± 0.027, 0.355 ± 0.021 
and 0.273 ± 0.028 and for oxycodone, the values were 0.690 ± 0.096, 0.499 ± 0.087, 0.153 ± 
0.01. For 18 month-old rats, Vmax value was 0.092 ± 0.003 for codeine compared to 0.153 ± 0.01 
for oxycodone. The Vmax value affected significantly (P ≤ 0.05) the enzyme-mediated clearance 
of these drugs (CLuint = Vmax / Km). The results of this study suggest that CYP2D enzyme 
undergoes a conformational change with age, particularly in 18 month-old rats considered to be 
geriatric in age, thus leading to a significant decrease in the rate of the formation of active opioid 
metabolites and a decrease in enzymatic clearance of these drugs. This study suggests that there 
is an impairment of CYP2D and CYP3A in aging rats, which affects their drug metabolism. 
 
Keywords: Opioids, Aging, Drug metabolism, CYP450, CYP2D, CYP3A, Mass spectrometry.  
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Introduction 
The recent advancement in the past decade in the medical field has led to an increase in the 
average life expectancy. In 2013, a survey showed that 14.1% of the US population are above the 
age of 65 and this is expected to increase to 21.7% by 2040 (Ortman et al., 2014). Elderly 
patients suffer from pain due to reasons, which include but are not limited to diseases. To 
improve the quality of life of these patients, they are prescribed medications for pain relief and 
life style changes that include eating healthy, losing a small amount of weight and increasing 
physical activity. 
Opioids are considered first-line therapy for pain relief. They are widely used for the 
management of all types of pain ranging from mild pain such as backache to severe pain such as 
post-surgical pain or cancer pain.  The pharmacokinetics and pharmacodynamics of opioids are 
known to be altered with aging (Mézière et al., 2013; Woodhouse & Wynne, 1988). Extensive 
research and literature reviews are available on this subject and some of the widely accepted 
explanations include decline in lean body mass, decrease in hepatic blood flow and disease 
conditions. In addition, studies suggest a decreased hepatic metabolism and renal clearance of 
drugs in elderly patients due to physiological aging or the presence of diseases like renal failure, 
hepatic failure and cardiovascular complications (Mangoni & Jackson, 2004). The reduction in 
hepatic clearance with age has not been satisfactorily elucidated and remains to some extent 
controversial. 
A large number of drugs are metabolized in the liver by CYP450 enzymes to active or inactive 
metabolites. The efficacy of the drugs bioactivated by CYP450 enzymes and the clearance of 
drugs metabolized by these enzymes are affected by any change in the activity of these enzymes. 
The isoforms of CYP450: CYP3A4, CYP2D6, CYP2C9, CYP2C19, CYP2C8 and CYP2B6 
contribute greatly to opioid metabolism in the body. CYP3A4 and CYP2D6 are the primary 
metabolizers of a large proportion of opioid drugs. Alteration in the functionality of CYP3A4 
and CYP2D6 with age leads to a change in the efficacy, safety, toxicity and side effects of these 
drugs. 
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Codeine and oxycodone are well-known substrates for CYP2D and CYP3A. Both drugs act on 
the µ-opioid receptor (MOR) in the CNS to cause analgesia. Codeine is metabolized by CYP2D6 
to morphine, to which it owes its analgesic effect, and by CYP3A4 to noroxycodone, an inactive 
metabolite. Oxycodone is metabolized to oxymorphone, an active metabolite and noroxycodone, 
an inactive metabolite by CYP2D6 and CYP3A enzymes respectively. In rats, it has been shown 
that CYP2D6 corresponds to CYP2D1 and CYP3A4 corresponds to CYP3A2 in terms of 
structure and function (Martigoni et al., 2006). Previous studies have shown that CYP3A is 
impaired in 18-month old rats leading to a decreased enzymatic clearance of ketamine 
(Santamaria R. et al. 2015).  
In general, drugs present in the pharmaceutical markets have not been sufficiently tested in 
geriatric and pediatric patients due to ethical considerations and regulatory restrictions. An 
understanding of factors that influence drug metabolism is important for a safe and effective 
drug use in the elderly. Enzyme modification can have a significant impact on the formation and 
elimination of active and inactive metabolites thus resulting in a profound effect on the 
pharmacological and toxicological outcomes.  
The aim of this research project was to study the effect of age in rats on the impairment of drug 
metabolism by CYP2D enzyme which can be due to a decrease in the metabolic function of the 
enzyme with age hence leading to a decrease in active metabolite formation and accumulation of 
parent drug in the body. In this study, rat liver S9 fractions from 3, 6, 12 and 18 month-old rats 
were used to evaluate the effect of aging on metabolic stability and enzyme-mediated clearance 
by CYP2D and CYP3A, based on Michaelis-Menten approach for specific metabolic pathways. 
Codeine and oxycodone were used to characterize functional changes since they are well-defined 
substrates for CYP2D and CYP3A functionality. HPLC-MS method was used to quantify 
codeine, norcodeine, morphine, oxycodone, oxymorphone and noroxycodone using isotopic 
dilution strategy in liver S9 fraction suspension. 
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I LITERATURE REVIEW 
I.1 Historical View of Opioids  
 
Around 3400 BC the Sumerians on Mesopotamia were among the first people to have cultivated 
the poppy plant, Papaver somniferum. They called it Hul Gil, the ‘joy plant’. Eventually the 
plant spread throughout the ancient world to every civilization in Europe and Asia and it was 
used to treat pain and many other ailments (Smith, 2009). 
 
The poppy plant was cultivated in the ancient civilizations of Persia, Egypt and Mesopotamia. 
Archaeological evidence and fossilized poppy seeds suggest that Neanderthal man may have 
used the opium poppy over thirty thousand years ago. Less controversially, the first known 
written reference to the poppy appears in a Sumerian text dated around 4,000 BC. Papaver 
somniferum has long been popular in Europe. Fossil remains of poppy-seed cake and poppy-pods 
have been found in Neolithic Swiss lake-dwellings dating from over 4,000 years ago. Poppy 
images appear in Egyptian pictography and Roman sculpture and opium could readily be bought 
on the street-markets of Rome. By the eighth century AD, opium use had spread to Arabia, India 
and China. The Arabs both used opium and organized its trade. 
 
A significant advance in opium-processing occurred in the sixteenth century. In freebase form, 
the alkaloids found in opium are significantly less soluble in water than in alcohol. Philippus 
Aureolus Theophrastus Bombastus von Hohenheim (1490-1541), better known as Paracelsus, 
claimed: "I possess a secret remedy which I call laudanum and which is superior to all other 
heroic remedies". He concocted laudanum [literally: "something to be praised"] by extracting 
opium using brandy, thus producing, in effect, tincture of morphine. Laudanum remained largely 
unknown until the 1660 when English physician Thomas Sydenham compounded a proprietary 
opium tincture that he also called laudanum, although it differed substantially from laudanum by 
Paracelsus. By the nineteenth century, vials of laudanum and raw opium were freely available at 
any English pharmacy or grocery store. 
 
Until the nineteenth century, the only opioids used medicinally or recreationally took the form of 
crude opium. Opium is a complex chemical cocktail containing sugars, proteins, fats, water, 
meconic acid, plant wax, latex, gums, ammonia, sulphuric and lactic acids, and numerous 
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alkaloids, most notably morphine (10%-15%), codeine (1%-3%), noscapine (4%-8%), 
papaverine (1%-3%), and thebaine (1%-2%). All of the latter, apart from thebaine, are used 
medicinally as analgesics. The opioid analgesics are of inestimable value because they reduce or 
stop pain without causing a loss of consciousness. They also relieve coughs, spasms, fevers and 
diarrhea. 
 
Even thebaine, though without analgesic effect, is of immense pharmaceutical value. This is 
because it can be used to produce semi-synthetic opioid morphine analogues such as oxycodone 
(Percodan), dihydromorphenone (Dilaudid), hydrocodone (Vicodin) and etorphine (Immobilon). 
Classes of morphine analogue include diphenylpropylamines (e.g. methadone), 4-
phenylpiperidines (e.g. meperidine), morphinans (e.g. levorphanol) and 6,7-benzomorphans (e.g. 
metazocine). Although seemingly structurally diverse, all these compounds either possess a 
piperidine ring or contain the critical part of its ring structure (Williams, 2011). 
 
Morphine was first isolated from opium in 1805 by a German pharmacist, Wilhelm Sertürner. 
who described it as the Principium somniferum. He named it morphium after Morpheus, the 
Greek god of dreams.  Doctors had long hunted for effective ways to administer drugs without 
ingesting them. Taken orally, opium is liable to cause unpleasant gastric side effects. The 
development of the hypodermic syringe in the mid-nineteenth century allowed the injection of 
pure morphine, after which it started being used for minor surgical procedures, for post operative 
and chronic pain and as an adjunct to general anesthetics. In 1874, English pharmacist C.R. 
Alder Wright boiled morphine and acetic acid to produce diacetylmorphine. Diacetylmorphine 
was then synthesized and marketed commercially by the German pharmaceutical company, 
Bayer and in 1898, Bayer launched heroin the best-selling drug-brand of all time made from 
morphine (Rassool, 2009). 
 
Codeine, a less powerful drug that is found in opium but can be synthesized, was first isolated in 
1830 in France by Jean-Pierre Robiquet, to replace raw opium for medical purposes. In 1874, 
chemists trying to find a less addictive form of morphine made heroin. But heroin had twice the 
potency of morphine, and heroin addiction soon became a serious problem. Methadone was first 
synthesized in 1937 by German scientists Max Bockmühl and Gustav Ehrhart at the IG Farben 
company. They were searching for a painkiller that would be easier to use during surgery, with 
less addiction potential than morphine or heroin. New painkillers that came to the market in the 
 5 
 
USA with approval from the Food and Drug Administration includes Vicodin in 1984, 
OxyContin in 1995 and Percocet in 1999. These are all synthetic opiates which mimic the body’s 
own painkillers. 
 
Opioids are considered to be the standard care for the management of acute and chronic pain, but 
long-term administration of opioids for the treatment of chronic non-cancerous pain is 
controversial (Rosenblum et al., 2008). The concerns related to the effectiveness, safety and 
abuse of opioids has led to two different approaches; the first one is a more restrictive 
perspective, whereas the second one is a greater willingness to endorse this treatment (Smith, 
2009). It was only after the publication of reports on the safety and efficacy of opioids prescribed 
to small numbers of patients with chronic non-malignant pain and the publication of a seminal 
article entitled “The Tragedy of Needless Pain” that opioid prescription for chronic non-
malignant pain began to be practiced. 
I.2 Opioids  
 
Opioids refer to compounds that bind to opioid receptors (OR) and exert their pharmacological 
or physiological effects on the body. An important effect of opioids is the reduction in the 
perception of pain. The human body has an innate pain relieving system made of endogenous 
opioids. Like their endogenous counter parts opioid drugs bind to OR to produce analgesia with 
some undesirable effects (Holden et al., 2005).  
I.3 Opioid receptors and their mechanism of action 
 
 OR and their respective genes have been characterized at cellular, molecular and 
pharmacological levels into four different OR systems µ-opioid receptor (MOR), k-opioid 
receptor (KOR), δ-opioid receptor (DOR), and opioid receptors like-1 (ORL-1) (Al-Hasani & 
Bruchas, 2011). OLR-1 is genetically closely associated with the previous three receptors, but 
displays a pharmacological profile that greatly differs from MOR, KOR and DOR as ORL-1 
does not bind opioid ligands (Connor & Christie, 1999; Mollereau & Mouledous, 2000). The 
MOR, KOR, DOR and ORL-1 receptors are encoded by OPRM1, OPRD1, OPRK1 and OPRL1 
genes respectively. The OR genes are highly conserved at the sequence encoding the seven 
transmembrane fragment but they vary at the carboxyl and amino termini. The difference in 
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affinity to opioid ligands and the distinct signaling pathways of the OR is a result of this 
variation (Levran et al., 2012). 
 
OR are expressed in the central nervous system and in the peripheral organs such as the heart, 
intestines, kidneys, lungs, liver and reproductive tracts (Abbadie et al., 2004; Beadles-Bohling & 
Wiren, 2005; Mansour et al., 1995; Villemagne et al., 2002; Vogt et al., 1995; Wittert et al., 
1996; Xia & Haddad, 1991, 2001). They are involved in a large number of physiological 
processes that include growth, reproduction, respiration, immunological response, physiology of 
the gastrointestinal tract (GIT) and pain signaling in the central and peripheral nervous system. 
The expression and distribution of OR vary among different organs and different species (Barry 
& Zuo, 2005). 
 
OR have been identified on cell bodies in the dorsal root ganglion and on central terminals of 
primary afferent neurons within the dorsal horn of the spinal cord (Stein et al., 1996). They have 
also been detected on peripheral nervous system on primary afferent neurons in animals 
(Coggeshall et al., 1997; Hassan et al., 1993; Li et al., 1996; Mousa et al., 2001; Stein et al., 
1990; Wenk & Honda, 1999) and in humans (Stein et al., 1996). The binding characteristics of 
OR on primary afferent neurons were shown to be very similar to those in the brain by binding 
experiments (Hassan et al., 1993). 
 
In the pain-modulation descending pathway, OR are expressed in the medulla and the 
periaqueductal gray area. They are also expressed in the limbic, the midbrain and the cortical 
structures (Al-Hasani & Bruchas, 2011). The activation of OR at these locations directly inhibits 
neurons, which in turn inhibits spinal cord pain transmission (Ahlbeck, 2011; McNicol et al., 
2003).  
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Figure 1: Sites of action of opioid analgesics. The ascending pathway shows the sites of central 
action on the pain transmission. The descending pathway shows the actions on pain modulating 
neurons in the mid brain and medulla. 1- Opioids can act directly on peripheral tissue. 2- 
Inhibition of pain by opioids can takes place at the spinal cord. 3- Some opioids act directly on 
the brain to relieve pain. Adapted from Al-Hasani & Bruchas, 2011.  
 
OR are G-protein-coupled receptors with seven transmembrane-spanning domains and are 
present on neuronal cell membranes. G-proteins consist of α, β and γ subunits. The α subunit is 
coupled with a guanosine diphosphate (GDP). When an agonist binds to an OR, it causes a 
conformational change leading to the attachment of guanosine triphosphate (GTP) to the α-
subunit, which in turn dissociates it from the β-γ stable dimer and the receptor (Fig.2). Both the 
α-subunit and β-γ stable dimer can modulate several cellular signaling pathways (Childers et al., 
1979; Childers & Snyder, 1978; Gether, 2000). These include among others, stimulation or 
inhibition of adenylate cyclase (Gether, 2000; Minneman & Iversen, 1976), activation of 
phospholipases and regulation of potassium and calcium channels.  This complex along with the 
β and γ group subsequently act on different intracellular pathways (Childers et al., 1979; 
Childers & Snyder, 1978) (Fig.2) 
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Figure 2: Activation cycle of G-proteins by G-protein-coupled receptors. 1-An agonist binds to 
the G-coupled protein receptor. 2- Agonist activates the G-coupled protein receptor. 3- 
Conformational change takes place. 4- Due to the conformational changes the attachment of 
GTP to the α-subunit takes place 5- α-subunit with GTP dissociates from the β-γ stable dimer. 
Both the α-subunit and β-γ stable dimer modulate several cellular signaling pathways. 6- Once 
energy is used the α-subunit with GDP reunites with the β-γ stable dimer until it is activated 
again.  Adapted from Jähnichen S, 2006. 
 
OR have also been shown to promote Ca2+ influx, stimulate phosphoinositide hydrolysis and 
stimulate adenylyl cyclase (Powell et al., 2002). Figure 3 illustrates one example of the 
mechanism of opioid action. 
 
 9 
 
 
Figure 3: One example of the mechanism of opioid action. When an opioid binds to an OR in 
the membrane of a neuron, calcium channels close, blocking positively charged calcium ions 
from entering the cell. In addition, cAMP levels decrease and potassium channels open, allowing 
positive potassium ions to exit the cell. These events hyperpolarize the cell, increasing the charge 
difference between the cell’s interior and the extracellular environment and making the neuron 
less likely to fire an action potential. Adapted from Grens K, 2011. 
 
The activation of all three types of OR by an agonist leads to the inhibition of adenylyl cyclase 
and modulation of membrane Ca2+ and K+ conductance. The increase in the K+ conductance and 
decrease in Ca2+ conductance by opioids reduces membrane excitability and contributes to the 
analgesic property of opioids. The inhibition of cAMP by opioids implies a more complex 
pathway for opioid regulation of cellular mechanism (Gong et al., 1998).  
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Figure 4: Pre- and post-synaptic effects of MOR agonists on synaptic transmission. Opioids 
specifically depress neurotransmitter release from nociceptive Aδ-fiber and C-fiber via 
presynaptic inhibition mediated by an inhibition of N-type, and to a lesser extent of P/Q-type 
voltage-dependent Ca2+-channels. Opioids regulate neuronal excitability and transduce receptor 
activation to downstream signal transduction pathways via the postsynaptic inhibition. 
 
Some opioids bind presynaptically to MOR on the central terminals of primary afferent 
nociceptive nerve fibres and others post synaptically on superficial dorsal horn neurons (Fig.4). 
KORs are located presynaptically on primary afferent neurons in the dorsal horn of the spinal 
cord where they participate in the inhibition of the release of excitatory neurotransmitter such as 
substance P, calcitonin gene-related peptide and glutamate. DORs are present on postsynaptic 
terminals of secondary order neurons and they decrease the excitability caused by the activation 
of other postsynaptic receptors such as neurokinin-1 receptor and N-methyl-D-aspartate. MORs 
are located either at presynaptic or postsynaptic terminals, therefore, they can either modulate the 
release of excitatory neurotransmitters or decrease the excitability of postsynaptic receptors 
(McDonald & Lambert, 2015).  Presynaptic MORs not only inhibit neurotransmitter release of 
gamma-amino butyric acid (GABA), but they also decrease the inhibition of dopamine pathways 
causing more dopamine to be released. Exogenous opioids through this mechanism cause 
inappropriate dopamine release which leads to abnormal synaptic plasticity causing addiction. 
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I.3.1 Endogenous opioids 
 
Endogenous opioids are opioid peptides released by neurons. There are four families of 
endogenous opioid peptides: endorphins, enkephalins, dynorphins and a recently classified 
family called endomorphins. All these peptides are derived by the cleavage of larger protein 
precursors. The precursors prepro-opiomelanocortin, preproenkephalin and preprodynorphin, 
which are encoded by three corresponding genes code for enkephalins, endorphins and 
dynorphins respectively (Koneru et al. 2009).  
I.3.1.1 Endorphins 
 
Endorphins are endogenous polypeptides that are considered natural painkillers. In vertebrate 
animals during strenuous exercise, excitement, pain and orgasms, the hypothalamus and pituitary 
gland produces endorphins, which causes the feeling of well-being and analgesia (Sprouse-Blum 
et al., 2010). Endorphins act by binding to MOR, hence causing analgesia and a sense of 
euphoria. They also cause the release of many sex hormones. There are four types of endorphins 
present in the body α-, β-, δ- and γ-endorphins, the most important and powerful endogenous 
opioid neurotransmitter is the β-endorphins. In the CNS, β-endorphins primarily bind to the 
presynaptic MOR inhibiting the release of GABA, thus resulting in excess production of 
dopamine. In the peripheral nervous system, β-endorphins bind to MOR both pre- and post-
synaptically and inhibit the release of tachykinin, particularly substance P, a key protein 
responsible for the transmission of pain (Sprouse-Blum et al., 2010). β-endorphins have the 
highest affinity for MOR, with medium affinity for DOR and lowest affinity to KOR (Holzer, 
2014). 
I.3.1.2 Enkephalins 
 
Nociception in the body is partly regulated by pentapeptides called enkephalins. Proenkephalin 
and prodynorphin are proteolytically cleaved into enkephalin peptides (Orduna & Beaudry, 
2016). Enkephalins exist mainly in two forms: met-enkephalin and leu-enkephalin, both of 
which are found in abundance in the brain and endocrine tissues (Michael Comb et al., 1982). 
They are also expressed in the gut, where OR agonists interact with pathways of the enteric 
nervous system that regulate GI motility and secretion (Hughes et al., 1977).  They play an 
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important role in the behavior, cardiac function, cellular growth, immunity and ischemic 
tolerance. Among their functions are pain perceptions, mood and behavior by altering emotional 
responses as well as acting on cardiovascular and respiratory functions (Przewlocki & 
Przewlocka, 2001). Enkephalins are distinguished by their C-terminal amino acid sequence, the 
opioid motif of met-enkephalin consists of Tyr–Gly–Gly–Phe–Met, whereas for leu-enkephalin 
it consists of Tyr–Gly–Gly–Phe–Leu (M. Comb et al., 1982). Their selectivity for DOR is 
moderately higher than MOR (Nieto et al., 2005).  
I.3.1.3 Dynorphins 
 
Dynorphins are formed by the cleavage of precursor proteins called prodynorphin by protein 
convertases (Berman et al., 2000; Day et al., 1998). Two types of dynorphins are formed: 
dynorphin A and dynorphin B. They are a family of endogenous opioid peptides that have potent 
analgesic effects and have been identified as neuropeptides involved in endogenous pain 
inhibition (Kuner, 2010; Mika et al., 2011). They are produced in different parts of the brain 
including midbrain, hippocampus, pons, medulla and spinal cord. They are also responsible for 
homeostasis, appetite control, pain regulation and body temperature regulation (Koneru et al. 
2009). They exert their effects through KOR. The KOR and the endogenous dynorphins are rich 
in the ventral tegmental area, nucleus accumbens, and prefrontal cortex, brain regions that 
regulate mood and motivation. Neurochemical and electrophysiological data have shown that 
KOR activation in these regions decreases dopamine transmission (Shippenberg et al., 2007) that 
maybe effective in the treatment of depression and drug addiction (Shippenberg, 2009). 
I.3.1.4 Endomorphins 
 
Endomorphins have a key role in pain perception, responses related to stress and complex 
functions such as reward, arousal and vigilance (Fichna et al., 2007). These tetrapeptides differ 
from the other known endogenous opioid peptides through their amino acid sequence, in which 
tyrosine residue is followed by glycine. All other endogenous opioids share the Tyr-Gly-Gly-Phe 
amino acid sequence at the N-terminus. Endomorphins are widely distributed in the CNS and 
have the highest known affinity and specificity for MOR. There are two types of endomorphins: 
endomorphin1 and endomorphin2. Both inhibit nociceptive transmission in the spinal cord 
through MOR (Przewlocki et al., 1999). 
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Endogenous opioids Affinity for OR 
MOR DOR KOR 
β-Endorphins +++ ++ - 
    Endomorphin-1 +++ - - 
    Endomorphin-2 +++ - - 
    Met-enkephalin ++ +++ - 
    Leu-enkephalin + +++ - 
Dynorphin-A + - +++ 
Dynorphin-B + + +++ 
Table 1. Summary of the affinity of endogenous opioids to specific receptors. (Merg et al., 2006; 
Raynor et al., 1994; Stein et al., 2009) 
 
OR CNS location  Response on activation 
MOR Brain ( laminae III and IV 
of the cortex, thalamus, 
periqueductal gray), spinal 
cord (substantia 
gelatinosa) 
supraspinal analgesia, physical 
dependence 
respiratory depression, miosis, 
euphoria, reduced GIT motility 
DOR Brain (pontine nucleus, 
amygdala, olfactory bulbs, 
deep cortex). 
Analgesia may be associated with 
mood change 
KOR Brain (hypothalamus, peri-
aqueductal gray, 
claustrum), spinal cord 
(substantia gelatinosa) 
 
Spinal analgesia, diuresis, 
dysphoria, sedation, miosis, 
disrealization, dispersonalization 
Table 2. Summary of OR, their tissue location and the response to their activation resulting from 
the binding of endogenous opioids onto the receptors. Adapted from (Cherny, 1996). OR are also 
present in the autonomic nervous system, peripheral nerves and GIT, where they can mediate 
effects on heart rate, nociception and GIT motility. 
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I.4 Pharmacological drugs targeting opioids receptors  
I.4.1 Morphine 
 
Morphine is a naturally occurring opiate found in opium plant, Papaver somniferum.  It acts on 
the MOR present in the CNS to relieve pain. It is used to treat moderate to severe pain. Morphine 
is generally prescribed for inpatients or post-operative patients, it is also given to terminally ill 
patients. It has high abuse potential. Morphine exerts its effect by binding to MOR, KOR and 
DOR, but morphine has a higher affinity for MOR. Morphine can be administered orally, 
intravenously, rectally, subcutaneously, epidurally, by inhalation and by snorting (Martin et al., 
2016). The liver metabolizes morphine to morphine-6-glucuronide (M-6-G) and morphine-3-
glucuronide (M-3-G) both of which are then excreted through the kidneys. M-6-G is more potent 
than morphine (Frances et al., 1990) and it is said to have higher affinity for the DOR than the 
MOR. M-6-G is also suggested to be safer than morphine because it causes lower respiratory 
depression due to the difference in their affinities towards the OR (Kilpatrick & Smith, 2005). 
The side effects of morphine include nausea, vomiting, constipation, myosis, sedation, 
drowsiness, allergy, euphoria, delirium, tolerance and respiratory depression. The adverse effects 
of morphine on the recovery of locomotor function may be linked to the activation of the KOR 
(Aceves et al., 2016). Studies performed on knockout mice lacking the MOR, show that mice 
display no morphine-induced analgesia (Matthes et al., 1996) or respiratory depression 
(Romberg et al., 2003) with morphine, suggesting that the two effects are closely linked. 
Morphine is the standard drug against which all other opioid analgesics are compared. 
I.4.2 Codeine 
 
Codeine has significantly lower affinity to MOR in comparison to morphine (Knaggs et al., 
2004). Codeine is converted to morphine by CYP2D6 in the liver and imparts its analgesic action 
through morphine (Desmeules et al., 1991; Sindrup et al., 1990). It is also converted by CYP3A4 
to norcodeine, which is reported to be an inactive metabolite. It is considered to be the agent of 
choice for the treatment of mild to moderate pain in both adults and children. Side effects of 
codeine include dizziness, shortness of breath, nausea and vomiting, which are all due to its 
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opioid effect. Severe adverse reactions to codeine include respiratory depression, circulatory 
depression, respiratory arrest, shock and cardiac arrest (Barh et al., 2013). 
 
Codeine is used as an antitussive in some cough-suppressing drugs. Cough is normally caused by 
the activation of cough reflex arc that includes vagal afferent nerves, cough center in the medulla 
and the efferent nerves. Inhibition at any site of this arc relieves cough. The antitussive effect of 
codeine is thought to be primarily by activation of the MOR and KOR receptors. Binding studies 
have demonstrated that codeine is more selective for MOR than KOR or DOR receptor (Kotzer 
et al., 2000; Mignat et al., 1995). KOR agonists also have antitussive activity, therefore, both 
MOR and KOR are considered as candidates for being the receptors, which contribute to its 
antitussive activity (Takahama & Shirasaki, 2007). Codeine is one of the well-characterized 
drugs used for analyzing the function of CYP2D enzyme in the liver. An elaboration on codeine, 
its pharmacokinetics, pharmacogenomics and pharmacodynamics is discussed in chapter III. 
I.4.3 Oxycodone 
 
Oxycodone is a semisynthetic opioid analgesic made from thebaine, a naturally occurring opioid 
alkaloid in the opium plant (Freund et al., 1999). Oxycodone is prescribed for moderate to severe 
pain and produces analgesia via the MOR. Oxycodone also has some affinity for a subtype of 
KOR and little to no affinity for DOR (Lalovic et al., 2006; Nielsen et al., 2007; Virk & 
Williams, 2008). In vitro and in vivo data suggest differences in the mechanism of action of 
morphine and oxycodone (Smith, 2008). Pretreatment with norbinaltorphimine, a KOR-selective 
antagonist blocks antinociception of intracerebroventricular oxycodone, but not morphine and 
pretreatment with MOR-selective antagonist naloxonazine blocks intracerebroventricular 
morphine but not oxycodone (Nielsen et al., 2007).  
I.4.4 Naloxone 
 
Naloxone is known to block or reverse the effects of opiate medications, which includes extreme 
drowsiness, respiratory depression, mental depression and loss of consciousness (Hardman JG & 
Limbird LE, 2006), and as such, is used for the treatment of mild to severe overdose with 
opioids. Reversal of respiratory depression caused by overdose with partial opiate agonists, may 
be incomplete or may require higher doses of naloxone. Intravenous naloxone acts within two 
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minutes and its effect lasts for thirty minutes, because of its short time effect compared to longer 
acting effect of opioids, multiple doses of naloxone is required to reverse the effects of opioids. 
In opioid abusers, naloxone can precipitate abrupt withdrawal symptoms such as body aches, 
restlessness, anxiety, tachycardia and seizure. Naloxone has been reported to be a MOR inverse 
agonist (Sirohi et al., 2009). Published data suggests that naloxone has 9-fold higher affinity for 
MOR in comparison to KOR and 60-fold greater affinity to DOR (Codd et al., 1995). Naloxone 
in the absence of opioids has not been documented to have any effect on the body since it is a 
competitive antagonist of OR. 
I.4.5 Naltrexone  
 
Naltrexone and its active metabolite 6ß-naltrexol are antagonists at the MOR, KOR to a lesser 
extent and DOR to a possibly insignificant extent. It is used in the management of opioid 
dependence. Despite being approved by the FDA for opioid addiction it is more frequently used 
for alcoholism. Ultra-low doses of naltrexone influence morphine analgesia and tolerance 
through spinal cord action. These doses increase acute morphine analgesia, whereas a high dose 
of naltrexone blocks analgesia. Furthermore ultra-low doses of naltrexone inhibits the 
development of morphine tolerance and partially restores morphine potency in animals 
previously showing tolerance (Ling et al., 1986). Recent studies in mice showed that ultra-low 
doses of systemic naltrexone augment morphine-induced analgesia and inhibit the development 
of tolerance and/or physical dependence. 
I.4.6 Tramadol  
 
Tramadol is a centrally acting opioid analgesic closely related to codeine and morphine. 
Tramadol consists of two enantiomers, tramadol and O-desmethyltramadol, both of which 
contribute to analgesia via different mechanisms and both are agonists at MOR. Tramadol also 
inhibits serotonin and norepinephrine reuptake thus enhancing the inhibitory effects on pain 
transmission in the spinal cord. Tramadol is metabolized in the liver by CYP2D6 to O-
desmethyltramadol, which is an active metabolite. It also gets metabolized by CYP2B6 and 
CYP3A4 to N-desmethyltramadol, an inactive metabolite. It undergoes Phase II conjugation 
reaction to form glucuronides and sulphates. Tramadol and its metabolites are mainly excreted 
by the kidneys. A wide variability in the pharmacokinetic properties of tramadol can be partially 
attributed to CYP polymorphism. Tramadol is effective in reducing pain caused by trauma, renal 
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or biliary colic, labour and chronic pain of malignant or non-malignant origin especially 
neuropathic pain. Due to its dual mechanism of action tramadol is useful in opioid-resistant 
chronic pain. 
I.4.7 Fentanyl  
 
It is a semisynthetic opioid that is 50 to 100 times more potent than morphine. It was introduced 
into clinical practise in the early 1960s. Fentanyl is a MOR agonist. It is used as an adjunct to 
general anaesthesia and to induce and maintain anaesthesia. The off label indications of fentanyl 
include its use as an analgesic for severe pain. Fentanyl contains a boxed warning for respiratory 
depression even at low therapeutic doses, which is caused by its direct action on the brain stem 
respiratory centers. It also depresses cough reflex by direct action on the cough center in the 
medulla. It is metabolized in the liver and intestinal mucosa by CYP3A4 isoform to norfentanyl. 
A study stated that fentanyl could modify the response to noxious pressure in inflamed paws via 
a peripheral site of action in rats, thus suggesting that it has possible role in the modulation of 
nociception in inflamed tissues via peripherally located opioid receptors (Stein et al., 1988). 
 
Drugs  Affinity for OR Metabolic pathway in human MOR DOR KOR 
Morphine Agonist Weak agonist Weak agonist Glucuronidation 
Codeine Weak agonist Weak agonist -	 CYP3A4, CYP2D6 
Fentanyl Agonist Agonist Weak Agonist CYP3A4 
Oxycodone Agonist -	 Strong agonist CYP3A4, CYP2D6 
Oxymorphone Agonist -	 -	 Glucuronidation 
Naltrexone Antagonist -	 - - 
Naloxone Antagonist Antagonist Antagonist - 
Tramadol  Agonist -	 -	 - 
Fentanyl  Agonist -	 -	 - 
Methadone Agonist Strong agonist Weak agonist CYP3A4, CYP2B6, CYP2C8, CYP2C19 
Table 3: Affinity of some of the commonly used opioids along with their metabolic pathway and 
the effect produced (Smith & Peppin, 2014). 
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I.5 Codeine  
I.5.1 Physico-chemical properties of codeine 
 
Codeine is chemically known as methyl morphine (C18H21NO3) and has a molecular weight of 
299.36424 g/mol. It is obtained either naturally from Papaver somniferum plant or by 
methylation of morphine.  
 
 
 
Figure 5: The molecular structures of codeine and morphine.  
 
The stronger analgesic activity of morphine is attributed to the free hydroxyl group at C3 
enabling a high affinity receptor binding whereas a low affinity receptor binding was reported 
for codeine (Mignat et al., 1995). The methylation of the hydroxyl group of morphine led to a 
more lipophilic compound that is codeine (Kay et al., 1967).  
I.5.2 Metabolism of codeine 
 
Codeine is metabolized in the liver by CYP2D and CYP3A to form primary metabolites 
including morphine and norcodeine (Caraco et al., 1996). Figure 6 represents the metabolic 
pathway of codeine in the liver. Codeine by itself is not an analgesic; it is only through its 
Codeine  Morphine 
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conversion to morphine by CYP2D in the liver that it expresses its analgesic effect (Desmeules 
et al., 1991; Sindrup et al., 1990). 
 
The affinity of codeine to the MOR is very low compared to morphine, which has 200 folds 
higher affinity for the receptor than codeine (Chen et al., 1991; P. Madadi & Koren, 2008; Yue 
et al., 1991). Morphine is one of the most potent opioid drugs present in the market and hence 
the analgesic effect felt after taking codeine is, without doubt, due to the morphine generated 
after its metabolism. Morphine is further converted to M-6-G and M-3-G by glucuronidation. 
Since codeine is metabolized by CYP2D enzyme into morphine, any changes in the enzymatic 
activity of CYP2D will lead to a variation in its pharmacological effect, which includes codeine 
efficacy in terms of pain relief, toxicity due to its accumulation and side effects exacerbation. 
 
Figure 6: Drug-metabolizing enzymes involved in the metabolism of codeine. In human, 
codeine is bioactivated by CYP2D6 to morphine and demethylated by CYP3A4 to norcodeine an 
inactive metabolite. Adapted from Stamer et al. 2010. 
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I.5.3 Effects of codeine:  
 
Codeine acts on the CNS by acting as an analgesic. Other effects include anxiolysis, euphoria 
and feelings of relaxation. A direct effect of codeine on the brain stem respiratory centres can 
cause respiratory depression. On the vascular system, it is known to produce peripheral 
vasodilatation that could cause orthostatic hypotension and fainting. Similar to other opioids, it 
can cause histamine release, which plays a role in opioid-induced hypotension. Histamine release 
may cause pruritus, flushing, red eyes and sweating. Effects of codeine on the GIT include 
decrease in gastric, biliary and pancreatic secretions resulting in indigestion. It can also cause a 
reduction in motility and an increase in tone in the atrum of the stomach and duodenum. In the 
small intestine, propulsive peristaltic waves in the colon are decreased, while tone is increased 
which results in constipation. Table 4 is a summary of codeine and some of its effects on 
important organs in the body. 
Codeine 
Site  Effects  
Central nervous system Analgesia, anxiolysis, euphoria, relaxation. 
Respiratory system  Respiratory depression. 
Cardiovascular system Orthostatic hypotension 
Gastrointestinal tract 
Decrease gastric, biliary and pancreatic secretions; decrease 
gastrointestinal tract motility, constipation. 
Table 4: Codeine and some of its effects on important organs in the body. 
I.5.4 Excretion 
 
Codeine and its metabolites are excreted primarily by kidneys in humans, monkeys and dogs 
(Casarett & Doull, 1977). Urinary excretion is rapid with approximately 67% of total alkaloids 
being eliminated in the urine within 6 hours after the administration of the drug. Excretion is 
almost complete by 24 hours, but trace amounts of codeine and its metabolites can still be found 
in urine for several days. Codeine metabolites were determined by using HPLC in urine of male 
rats. Unchanged codeine, codeine glucuronide, free morphine and morphine-3-glucuronide were 
detected in 24 hours urines of the rats. Codeine is metabolized by glucuronidation and by 
oxidative N- and O-demethylation in rats (Oguri et al., 1990) 
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I.5.5 Pharmacokinetics 
 
Codeine is readily absorbed from the GIT and has a reported oral bioavailability of 80.5% ± 
30.9% (Guay et al., 1988). It is rapidly distributed from blood to body tissues, passes the blood 
brain barrier and is found in fetal tissues and breast milk. Lipophilicity of codeine from reported 
literature was found to be 0.60 (octanol/pH 7.4) + 0.89 (Moffat et al., 2005; Moffat, 1986). The 
apparent volume of distribution of codeine has been reported to be approximately 3-6 L/kg 
indicating extensive distribution of the drug into tissues. The total body clearance, renal 
clearance and non renal clearance of codeine were reported to be 15.0 ± 3.4 ml/min/kg, 1.71 ± 
0.78 ml/min/kg and 13.32 ± 2.83 ml/min/kg (Guay et al., 1988). The reported half-life of codeine 
in humans is about 2.9 hours. 
Table 5 presents data collected from different publications where the pharmacokinetics of 
codeine was evaluated.  
Species  Dose  AUC  Vd  CL T1/2 Reference  
Rats 3mg/kg (i.v) 30279 ng.min/mL 5.1 L/kg 6.3 l/kg/hr 39.6 min (Shah & Mason, 1990) 
Rats  5mg/kg (oral) 4074 ng.min/mL - 6.2 l/kg/hr 34.1 min 
Greyhound 
dogs  
1.43 mg/kg 
(oral) 30.53 h.ng/mL - - 1.6 h 
(KuKanich, 2010) Beagles 
dogs  
0.9 mg 
codeine/ml in 
solution (oral) 
8.34 ng/h/mL - - 2.67 h 
Humans 		
PM 30 mg 180 ug.h/l - - 4.8 h 
(Kirchheiner et al., 2007) EM 30 mg 191 ug.h/l - - 3.6 h 
UM 30 mg 192 ug.h/l - - 3.7 h 
Humans 
60mg/70kg 734 h.ug/l - - 2.1 h 
(Kim et al., 2002) 
120mg/70kg 1800 h.ug/l - - 2.4 h 
Humans 60 mg (oral) 1262.4 ng.mL/h - - 2.6 h 
(Band, Band, Deschamps, 
Besner, & Coldman, 
1994) 
Humans 30 mg (oral) 7.37% 389 l 2280 ml/min 1.47 h (Vree & Verwey-van Wissen, 1992) 
Humans 		
EM 50 mg (oral) 1010 nmoll-1h 		 2.10 l/h/kg 2.43 h 
(Yue et al., 1991) 
PM 50 mg (oral) 1020 nmoll-1h 		 1.92 l/h/kg 2.90 h 
Humans  60 mg (oral) 649 ng/ml/hr 6 L/kg 15.3 ml/min/kg 4.5 h (Guay et al., 1988) 
Table 5: Pharmacokinetic data of codeine collected from different publications show a wide 
variability in the values reported. The – represents values that were not reported. Abbreviations 
PM, EM and UM described in legend. 
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I.5.6 Pharmacogenetics 
 
Recent studies showed that the pharmacokinetics of codeine varies between individuals and can 
only be described via pharmacogenomics of CYP2D6 polymorphism. Humans can be 
categorized according to CYP2D6 polymorphism into poor metabolizers (PM), intermediate 
metabolizers (IM), extensive metabolizers (EM), and ultra-rapid metabolizers (UM). CYP2D6 
alleles are characterized as normal function, reduced function and non-functional based on the 
expected activity level of the enzyme for which they encode (Crews et al., 2012). Two non-
functional alleles result in PM phenotype, at least one reduced functional allele in IM and at least 
one functional allele in EM, multi copies of a functional allele, due to duplication or multiple 
duplications of the CYP2D6 gene in UM phenotype (Table 4). In UM and EM a large dose of 
codeine is metabolized to morphine leading to morphine toxicity that can cause severe 
respiratory depression and death. In PM codeine is not converted to morphine and hence the 
affected individuals do not experience any analgesia from codeine and thus continue to 
experience pain (Table 6). 
Table 6: Recommended dosage of codeine based on CYP2D6 phenotypes. Adapted from Crews 
et al., 2012. 
  
Likely 
phenotype  Genotypes  
Implications of codeine 
metabolism  
Codeine therapy 
recommendation 
Ultrarapid 
metabolizer 
An individual carrying 
more than two copies of 
alleles. 
Increased formation of 
morphine following codeine 
administration leading to 
higher risk of toxicity. 
Avoid codeine use due 
to potential toxicity. 
Extensive 
metabolizer 
An individual carrying 
two alleles encoding full 
function allele together 
with reduced-function 
allele. 
Normal morphine formation. 
Use label recommended 
age or weight-specific 
dosing. 
Intermediate 
metabolizer 
An individual carrying 
one reduced and one non-
functional allele. 
Reduced morphine formation. 
Use label recommended 
age or weight-specific 
dosing. If no response, 
consider alternative 
analgesics such as 
morphine or non-opioid. 
Poor 
metabolizer 
An individual carrying no 
functional alleles. 
Greatly reduced morphine 
formation following codeine 
administration leading to 
insufficient pain relief. 
Avoid codeine use due 
to lack of efficacy. 
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Studies show that morphine AUC after codeine administration varied more than 30-fold between 
PM and UM groups (Johansson et al., 1991; Mikus et al., 1994; Mortimer et al., 1990; Yue, et 
al., 1997). A strong correlation between the number of active CYP2D6 genes and plasma 
concentrations as well as urinary recovery ratios of all O-demethylated codeine metabolites was 
observed. The plasma concentrations and AUCs of morphine between UMs and EMs differed 
about 1.5-fold with a nearly exact linear gene-dose effect. There was an almost exact linear 
relationship between the number of active CYP2D6 gene copies and codeine total clearance. The 
metabolic ratios calculated as codeine/morphine and (codeine+Codeine-6-
Glucuronide)/(morphine+M-3-G+M-6-G) varied significantly depending on CYP2D6 activity. 
Cases have been reported of adults with UM phenotype suffering opioid toxicity even with small 
doses of codeine (Madadi et al., 2009).  
 
In PMs, the ratios were about 10-fold higher compared to EM or UM. A significant trend 
towards lower ratios with increasing CYP2D6 activity was observed. UM resulted in a 1.5-fold 
higher morphine production compared to EM. This difference is only moderate but the risk for 
opioid intoxication might be increased in UMs if other additional factors such as reduction in 
renal function or inhibition of other enzyme systems occur at the same time (Kirchheiner et al., 
2007). When sedation and miosis as opioid effect-related parameters are observed a slight 
decrease in pupil diameter in all groups was observed but no CYP2D6 genotype-related effects 
on miosis have been detected. A longer period of miosis was observed in PM though not 
statistically significant (Kirchheiner et al., 2007). Significant variability in both the 
pharmacokinetics and pharmacodynamics of codeine has been shown in animal and adult human 
laboratory experimental studies (Chen et al., 1991; Cleary et al., 1994; Eckhardt et al., 1998; 
Mikus et al., 1991). 
I.5.7 Effect of age 
 
It has been suggested that neonates and infants have a reduced metabolic capacity for codeine as 
CYP2D6 activity is, at most, less than 1% of the adult values in foetal liver microsomes 
(Quiding et al., 1992). CYP2D6 expression rapidly reaches adult levels within the first 6 months 
of age (Stevens et al., 2008). Although another study suggests that enzyme activity may be less 
than 25% of adult values up to 5 years of age (Tateishi et al., 1997). CYP2D6 genotype seems to 
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be concordant at 2 weeks of age (Madadi et al., 2009). A significant relationship between 
phenotype and plasma morphine was shown in children (Sindrup & Brøsen, 1995).  
 
The United States Food and Drug Administration (FDA) have recently issued a boxed warning 
contraindicating the use of codeine after tonsillectomy and/or adenoidectomy in children. Post 
operatively, children suffering from obstructive sleep apnea passed away after therapeutic doses 
of codeine were prescribed. The children were later confirmed to be UM of codeine and may 
have suffered from breathing problems, but it is hard to determine UM in children and hence 
codeine has been contraindicated (Ciszkowski et al., 2009; Kelly et al., 2012). Three fatal or life 
threatening cases have been reported in children. The fatal cases had functional gene duplication 
encoding for CYP2D6 caused a greater production of potent morphine from codeine. Severe 
respiratory depression in an EM was also reported (Caraco et al., 1996). Health Canada has also 
reviewed the safety of prescription of codeine in children and it no longer recommends its use in 
children less than twelve years of age. It can be used to stepdown from stronger opioids in 
instances when a patient’s pain is decreasing over time (Ginsburg et al., 2009). 
 
In children antitussive dosages of 3-5 mg/kg/d have produced somnolence, ataxia, miosis, 
vomiting, rash, facial swelling and pruritus. Respiratory depression requiring mechanical 
ventilation occurred in 3% of children receiving doses greater than 5 mg/kg/d. Hepatic 
glucuronidation pathway is completely underdeveloped in infants, which places them at 
particular risk for adverse dose-related effects. In adults a linear relationship has been shown to 
exist between a codeine dosage in the range of 7.5-60 mg/d and a decrease in chronic cough 
(Crews et al., 2012).  
 
Available research findings imply that age specific differences in the pharmacokinetics of 
codeine may be significant. In a comparison of i.m and rectal codeine administration in children 
aged 3 months to 12 years, peak plasma levels were achieved between 30 and 60 minutes in both 
groups but rectal bioavailability was found to be lower. The plasma drug concentration data 
indicates that a rectal dose of codeine of 0.5 mg/kg in children can result in similar or slightly 
greater plasma concentration of codeine and its metabolites than after 60 mg in adults (Williams 
et al., 2002). 
 
 25 
 
Furthermore, nursing mothers are advised not to take codeine. In one case, a 13-day old breast 
fed infant was reported dead, but the mother was on a less than usual amount of codeine 
prescribed for episiotomy. She was genetically tested and confirmed to be an UM. The amount 
of morphine in her breast milk was at a toxic level and hence the baby died of opioid toxicity 
(Madadi et al., 2007). Codeine is considered comparatively safe in the elderly and is still being 
prescribed (Chau et al., 2008).  A case of an elderly patient complaining of no pain relief after 
taking therapeutic doses of codeine, patient was confirmed to be a PM of codeine (Susce et al., 
2006).  
 
The role of codeine in treatment of the elderly is a subject of debate due to lack of evidence and 
common adverse effects experienced by them. Assessment, evaluation and treatment of pain can 
be very challenging due to alterations in the pharmacokinetics of opiates, which occur with 
normal physiological aging, polypharmacy, multiple comorbidities and the potential of more side 
effects or treatment failures are other problems that should be taken in consideration. Codeine is 
considered a safe analgesic however there have been calls to withdraw it from the market. A 
meta-analysis of opioids found that the modest benefits of codeine were outweighed by adverse 
effects in the treatment of osteoarthritis of the knee or hip (Iedema J., 2011). A cohort study 
found that the risk of injury was higher in older people using combination products of codeine 
than those taking other sedative drugs (Buckeridge et al., 2010).  
 
The variation in pharmacological effect from children dying of morphine toxicity to elder 
patients experiencing no analgesic effect with increased risk of adverse effects, makes us assume 
that there is a change in CYP2D6 activity with age. The variation of CYP2D6 metabolic activity 
with age, may lead to a change in phenotype from UM and EM metabolizers to PM. The patients 
may hence experience no analgesia and codeine might accumulate in their body systems causing 
opioid toxicity and lack of pain relief.  Overall the efficacy and side effects of codeine in 
different age groups has not so far been sufficiently investigated. 
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I.6 Oxycodone  
I.6.1 Physico-chemical properties of oxycodone 
 
Oxycodone is a semisynthetic opioid derived from the naturally occurring opium alkaloid, 
thebaine. Chemically oxycodone is a 4,5-alpha-epoxy-14-hydroxy-3-methoxy-17-
methylmorphinon-6-onehydrochloride. The molecular formula of oxycodone is C14H21NO4 and 
its molecular weight is 315.36364g/mol. 
 
 
  
Figure 7: The chemical structures of oxycodone and morphine.  
 
The structural difference between oxycodone and morphine means that oxycodone is not directly 
susceptible to phase II metabolism therefore it has greater bioavailability of 60-87% (Ordonez et 
al., 2007). Also because of the difference in structure, oxycodone causes less 
immunosuppression in comparison to other opioids. 
I.6.2 Metabolism of oxycodone 
 
In human, oxycodone is extensively metabolized by CYP2D6 and CYP3A4 in the liver to 
oxymorphone and noroxycodone respectively (Kalso, 2005). Systemic exposure to oxycodone 
and metabolically derived noroxycodone was approximately 2.3- and 6.4-fold higher in Dark 
Oxycodone Morphine 
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Agouti rats compared to Sprague-Dawley rats following a subcutaneous administration of single 
bolus of oxycodone at 2mg/kg whereas the circulating concentrations of metabolically derived 
oxymorphone remained very low (Huang et al., 2005). Oxymorphone is a more potent opioid 
receptor agonist than oxycodone, whereas noroxycodone is less potent and has weaker 
antinociception than the parent drug (Kalso, 2005). Noroxycodone undergoes further oxidation 
by CYP3A4 to noroxymorphone, which is active at opioid receptors but it, does not seem to 
cross the blood brain barrier. The glucuronide metabolic pathway for oxycodone has so far not 
been established. The analgesic effect of oxycodone is due to the parent drug itself but some 
analgesia is a contribution of one of the active metabolites oxymorphone, which is more potent 
than oxycodone, but is formed in small quantities. 
Figure 8: Drug-metabolizing enzymes involved in the metabolism of oxycodone. The major 
metabolic pathway of oxycodone is the formation of noroxycodone via CYP3A4 enzymes. 
Noroxycodone is further metabolised to noroxymorphone via CYP2D6 enzymes. The minor 
metabolic pathways are formation of oxymorphone via CYP2D6 enzymes, and 6-keto 
reduction to α-/β-oxycodol. Oxymorphone is further metabolised to noroxymorphone via 
CYP3A4 enzymes. Adapted from Andreassen et al., 2010 
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I.6.3 Effects of oxycodone 
 
Oxycodone imparts its analgesic effect by binding to specific CNS OR in the brain and spinal 
cord. It is a full opioid agonist that binds to KOR, MOR and DOR (Ordonez Gallego et al., 
2007). It has more affinity to the KOR than MOR or DOR in this order respectively. Studies 
suggest that its analgesic action is due to the activation of KOR in contrast to morphine which 
interacts primarily to MOR (Ross & Smith, 1997). Oxycodone produces analgesia without loss 
of consciousness. It induces cough suppression by direct action on the cough reflex center in the 
medulla. Cough suppression occurs at lower doses than generally required for anesthesia. 
 
Oxycodone acts directly on the brain stem respiratory center to produce respiratory depression. 
Both a reduction in the responsiveness of the brain stem respiratory centers to increase carbon 
dioxide tension and electrical stimulation are involved in the respiratory depression. Oxycodone 
causes peripheral vasodilatation, inhibits baroreceptor reflexes and decreases peripheral 
resistances. Oxycodone may also lead to histamine release and hence it may cause pruritis, 
flushing, sweating, red eyes and orthostatic hypotension. Like other opioid analgesic, nausea and 
vomiting is caused by direct stimulation of chemoreceptor trigger zone located in the medulla. It 
may also cause a decrease in hydrochloric acid secretion in the stomach, resulting in decreased 
motility. 
 
Oxycodone  
Site  Effects  
Central nervous system Analgesia, antitussive, miosis of pupils, 
respiratory depression. 
Cardiovascular system Orthostatic hypotension 
Gastrointestinal tract Decrease gastric, biliary and pancreatic 
secretions; decrease gastrointestinal tract 
motility, constipation, elevation in serum 
amylase. 
Table 7: Oxycodone and some of its effects on important organs in the body. 
 
When oxycodone is used for the relief of moderate to severe pain, it is available in immediate 
and controlled release dosage forms. Controlled release oxycodone is subject to abuse by drug 
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addicts who grind the tablets and use it for an immediate high dose effect, causing a sense of 
euphoria and increasing the possible risk of toxicity. The efficacy of oxycodone may be modified 
by CYP2D6 polymorphism due to a decrease in the clearance of the drug. However, since its 
therapeutic effect depends on the parent drug, CYP2D6 polymorphism may not affect the 
analgesic effect of oxycodone, but it might affect the toxicity profile. 
I.6.4 Oxycodone excretion 
 
The kidney is the primary excretion site for oxycodone and its metabolites. The total plasma 
clearance is approximately 1.4 L/min in adults. Most of oxycodone and noroxycodone is 
excreted in urine as the free unconjugated form whereas oxymorphone is mainly excreted in the 
conjugated form (Kalso, 2005). 
I.6.5 Oxycodone pharmacokinetics 
 
The pharmacokinetic parameters of oxycodone are shown in Table 7. The volume of distribution 
of oxycodone is 2-3 L/kg. The t1/2 is about 2-3 hours after i.v. administration and about 3 hours 
after immediate-release solution. The maximum plasma concentration of oxycodone are reached 
within 25 min after i.v administration and after 1.3 h after immediate-release (Kalso, 2005).  
 
A study reported that clearance of intravenous oxycodone was reasonably high (approximately 
0.8 L/min), which was predicted as a medium hepatic extraction and a moderate first-pass effect 
of oxycodone (Lalovic et al., 2006). The urinary metabolites derived from CYP3A4-mediated N-
demethylation of oxycodone (noroxycodone, noroxymorphone, and α- and β-noroxycodol) 
accounted for 45% ± 21% of the dose, whereas CYP2D6-mediated O-demethylation 
(oxymorphone and α- and β-oxymorphol) and 6-keto-reduction (α- and β-oxycodol) accounted 
for 11% ± 6% and 8% ± 6% of the dose, respectively (Lalovic et al., 2006).  In infants and 
neonates a large variability in clearance and t1/2 has been reported and hence routine dosing in 
this population might be dangerous (Pokela et al., 2005). The pharmacokinetics of intravenous 
oxycodone in children aged 6-93 months are fairly similar to those reported in adults (Kokki et 
al., 2004). A marked interindividual variation in the pharmacodynamics and pharmacokinetics of 
oxycodone was observed supporting the need for individualized dosing regimen (Lugo & Kern, 
2004) 
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Species  Drug and dose 
AUC 
(ng/ml/h) 
Cmax 
(ng/mL) Tmax (h) t1/2 (h) 
Vss 
(L/kg) 
CL 
(L/min) Bioavailability  Reference 
Human  
IRS 
oxycodone 
20 mg 
194 ± 23 
(0, 36 h) 
41.6 ± 
6.1 1.3 ±0.6 
3.2 
±0.9 - - - 
(Mandema, et 
al., 1996) 
Human  
IRS 
oxycodone 
0.28 
mg/kg 
245 ± 84 38 ±14 - 5.1 ± 1.7 - - 0.6 ± 0.2 
(Poyhia, et al., 
1992) 
Human  
I.V. 
oxycodone 
0.07 
mg/kg 
-	 -	 -	 2.3 (2-5.5) 
2.6 
(2.2-
3.0) 
0.78 
(0.5-
1.0) 
- (Pöyhiä, et al., 1991) 
Human  
I.V. 
oxycodone 
0.05 
mg/kg 
70 (52-
88) 
13 (9-
17) 0.42 (0.33-4) 
2.6 (2-
3.1) 
2.0 
(1.1 -
2.9) 
0.83 
(0.6-
1.0) 
 (Takala et al., 1997) 
Sprague 
Dawley 
rats 
I.V. 
5 mg/kg 
2957 ± 
204 - - 
0.7 ± 
0.1 
2.8 ± 
0.2 
4.9 ± 
0.3 - 
(Chan et al., 
2007) 
Sprague 
Dawley 
rats 
I.V. 
5 mg/kg 
4671 ± 
377 - - 
1.1 ± 
0.2 
2.2 ± 
0.2 
3.1 ± 
0.3 - 
(Chan et al., 
2007) 
Sprague 
Dawley 
rats  
Oral  
10 mg/kg 69 ± 9 43 ± 8 0.26 ± 0.12 
3.0 ± 
0.5 - - 1.2 
(Chan et al., 
2007) 
Sprague 
Dawley 
rats  
Oral  
10 mg/kg 470 ± 47 215±39 0.11 ± 0.03 
4.0 ± 
0.5 - - 5.0 
(Chan et al., 
2007) 
Table 8: Pharmacokinetics of oxycodone in humans and rats. Adapted from Chan et al. 2007 and 
Kalso, 2005. 
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I.6.6 Effect of age  
 
Pharmacokinetic of intravenous oxycodone were reported to be dependent on the age of patients. 
Patients aged 60-70, 70-8- or 80-90 years had 28-34% lower clearance of oxycodone than 
patients aged 20-40 years. The change in clearance of oxycodone lead to up to 80% higher 
exposure to oxycodone in the oldest group than in the youngest group. Patients aged above 70 
years are expected to have a 40-80% exposure to oxycodone than young adult patients (Liukas et 
al., 2011). 
 
A decrease in the elimination clearance of oxycodone with advancing age in reflected in the 
elimination half-life, which increased with increasing age. A significant increase in the time 
needed for 50% decrease in concentration after continuous infusion of variable length was seen 
in the elderly. The predicted time course after repeated bolus dosing of oxycodone showed that 
oxycodone may accumulate in the elderly compared to young adults. The predicted peak 
concentrations of oxycodone were also much higher in the elderly (Saari et al., 2012).  
 
In a comparative study between patients aged 70-90 years and 20-40 years, the former group had 
a 50-80% higher mean exposure to oxycodone and a twofold higher plasma concentration than 
the young adults after 12h ingestion of oral oxycodone. The apparent clearances were lower in 
the elderly patients than in the 20-40 group. The mean elimination half-life of oxycodone in the 
70-90 group was 1.6 h longer than in the youngest group. Age was found to be a significant 
covariate for oxycodone pharmacokinetics. In elderly patients, dosing should therefore be 
reduced and carefully titrated to avoid considerable accumulation of oxycodone and potentially 
hazardous side effects (Saari et al., 2012). These also data demonstrate that the elimination of 
oxycodone is reduced with advancing age 
 
In healthy volunteers with specific CYP2D6 genotyped and phenotyped, oxycodone analgesic 
effects were assessed in experimental pain tests. Differences depending on CYP2D6 activity was 
demonstrated in the analgesic response, UM experienced a 1.5- to 6-fold increase of the 
analgesic effects as compared with EM. PM had a 2–20-fold reduction of the effects as 
compared with EM. This is in agreement with the few case reports describing reduced analgesic 
effect of oxycodone in PM. 
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Differences according to CYP2D6 phenotype were similarly demonstrated in other assessed 
pharmacodynamic parameters (pupil size, saturation, sedation and psychomotor effects). 
Oxycodone had no significant effect on the pupil size of the genotypic PM whereas it induced a 
pupil constriction in all other volunteers. It had no effect on the sedation and saturation 
assessment in PM, whereas they were higher in UM than EM (Samer et al., 2010). Oxycodone 
treatment pro re nata was intolerated by an elderly patient who was previously noted with a 
long-standing intolerance to codeine, patient showed significant side effects with the drug (Susce 
et al., 2006). The pharmacokinetics of oral oxycodone were seen to depend upon the age of the 
patients and their CYP2D polymorphism. 
 
Likely phenotype  Genotypes  Recommendations for oxycodone therapy 
Ultrarapid metabolizer An individual carrying more than two copies of alleles. 
Use alternative drug to 
oxycodone, not codeine or 
tramadol or be alert to adverse 
drug events. 
Extensive metabolizer 
An individual carrying two alleles 
encoding full function allele together 
with reduced-function allele. 
Use label recommended age or 
weight-specific dosage. 
Intermediate 
metabolizer 
An individual carrying one reduced and 
one non-functional allele. 
Use alternative drug to oxycodone 
not codeine or tramadol or be 
alert to insufficient pain relief. 
Poor metabolizer An individual carrying no functional alleles. 
Use alternative drug to oxycodone 
not codeine or tramadol or be 
alert to insufficient pain relief. 
Table 9: Recommended dosage of oxycodone by CYP2D6 phenotypes. Adapted from Swen et 
al., 2011. 
I.7 Physiological and pharmacokinetic effects of aging 
 
Aging is a normal physiological phenomenon characterized by the progressive degeneration of 
organ systems and tissues. It has been defined as a complex multifactorial process and it is 
associated with numerous declines in physiological and cognitive functions that lead inevitably 
to death. Environmental factors such as diet, exercise, pollutants, exposure to radiation and 
pathogenic microorganisms influence the process of aging. Gender also plays a role in aging; in 
most developed countries women tend to outlive men by 7 to 10 years. Another factor that can 
influence aging is the individual’s genetic make up. The process of aging falls into three 
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categories with advancing age; changes in cellular homeostatic mechanisms, decrease in organ 
mass and decline and loss of functional reserve of the body’s system. 
 
There are various theories related to aging. The first interesting category of theories is that aging 
is ‘programmed’, where delineated biological alterations in homeostasis and natural defence will 
take place over time. The second category is the ‘error’ theory where it is assumed that the body 
undergoes progressive damage due to environmental insults. The third “free radical theory” 
suggests that reactive oxygen species generated during mitochondrial energy production are 
damaging because of free radicals with evidence of oxidative change to DNA, protein and lipids. 
 
Changes with age occur in every individual but not necessarily at the same rate for each organ 
and tissue. In the cardiovascular system, age leads to a decrease in elasticity and an increase in 
stiffness of the arterial system, resulting in an increase in the afterload on the left ventricle, an 
increase in the systolic blood pressure and left ventricular hypertrophy (Chen et al., 1998; 
Vaitkevicius et al., 1993). Furthermore the observed drop out in the pacemaker cells leads to a 
decrease in the intrinsic heart rate. In addition to that a decrease in the responsiveness to 
adrenergic receptor stimulation, decreases reactivity to baroreceptors, chemoreceptors and an 
increase in catecholamines which lead to all the diseases related to cardiovascular system 
(Cheitlin, 2003). These cardiovascular diseases seen in the elderly include, to name a few 
isolated systolic hypertension, diastolic dysfunction, heart failure, atrioventricular conduction 
defects and aortic valve calcification. The lungs are also affected with aging which causes the 
decrease in peak airflow and gas exchange, the decrease in vital capacity, the weakening of 
respiratory muscles and the decline in the effectiveness of lung defense mechanism. 
Aging has always been closely linked with a decrease in the renal elimination of drugs. The 
changes that take place in the kidney with age include a decrease in renal mass that reflects a 
reduction in nephrons, a decline in renal plasma flow and glomerular filtration rates and an 
average of 8mL/min/1.73cm2/decade decline in creatinine clearance after the age of 30 in 
humans (Dunnill & Halley, 1973; Glassock & Winearls, 2009; McLachlan, 1978). The decrease 
in creatinine clearance does not lead to a concomitant increase in plasma creatinine due to the 
related loss of muscle mass with age (Mangoni & Jackson, 2004). 
 
Hepatic metabolism of drugs by Phase I reactions is likely to be prolonged in the elderly (Klotz, 
2009) whereas no significant reduction in Phase II metabolism was observed (Le Couteur et al., 
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2002). For drugs with decreased metabolism, clearance typically decreases by 30 to 40%. 
Theoretically, drug dose should be decreased by the same percentage, but the rate of drug 
metabolism decline, varies between different individuals. . First pass metabolism of drugs, 
decrease with age, probably, due to the decrease in liver mass and blood flow, hence increasing 
the bioavailability of drugs (Mangoni & Jackson, 2004), but the bioavailability of prodrugs that 
require activation by the liver also decreases. A change in the absorption, distribution, 
metabolism and elimination of drugs is observed with age, with some changes having more 
profound effects on drugs than others. The metabolism and excretion of many drugs are known 
to decrease with age leading to prolongation of half life of drugs in the body (Mangoni & 
Jackson, 2004), hence increasing the systemic exposure of the body to the drug which might lead 
to toxicity and side effects. 
I.7.1 Absorption 
 
In elderly patients, a decrease in gastric emptying, an increase in pH and a decrease in small-
bowel surface area tend to be clinically inconsequential for most drugs with the exception of a 
few drugs where optimum pH is required, for example, for the absorption of calcium-carbonate. 
Pharmacokinetic studies on absorption in relation to age provide conflicting results. Although 
absorption does not seem to be affected for most drugs, supplements like vitamin B12, iron and 
calcium that require active transport across the intestine are reduced (Blechman & Gelb, 1999), 
whereas absorption of drugs like levodopa is increased perhaps due to a decrease in dopa 
decarboxylase (Klawans HL, 1990). 
I.7.2 Distribution 
 
It is known that with age there is a decrease in lean body mass, an increase in body fat and a 
decrease in total body water (Shi & Klotz, 2011). This leads to an increase in the volume of 
distribution of highly lipophilic drugs that may lead to an increase in their elimination half-life 
and volume of distribution. Polar drugs that are water-soluble tend to have smaller volume of 
distributions and hence higher serum levels in elderly patients (Cusack et al., 1979; Redolfi et 
al., 1979; Vestal et al., 1977). The reduction in the volume of distribution of water-soluble drugs 
in the elderly tends to be balanced out by a reduction in renal clearance with a very low effect on 
the half life of the drugs (Mangoni & Jackson, 2004). 
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I.7.3 Metabolism 
 
Clearance of drugs by the liver depends on the capacity of the liver to extract drugs from the 
blood passing through it and the hepatic blood flow rate. The formula: 
 
CLliver = 
! (!"!!")!"  = QE 
 
where E= steady state extraction ratio, Q=liver blood flow (sum of hepatic portal and hepatic 
arterial blood flow), Ca = concentration of drug in portal vein and hepatic artery, Cv = 
concentration of drug leaving the liver in the hepatic vein and CLliver = clearance by the liver 
depicts that clearance depends on the blood flow and the extraction ratio. Extraction ratio is 
dependent on the metabolizing capacity of the liver; in other words it is dependent on drug 
metabolism by the liver. 
 
The liver contains a large number of enzymes but the family of enzymes responsible for most of 
the drug metabolism are the CYP450 (Phase I) out of which the sub families CYP1A2, 
CYP2C19, CYP2C9, CYP2D6, CYP2E1, and CYP3A4 play an important role in drug 
metabolism (Cupp & Tracy, 1998). The main aim of the body in metabolizing drugs is to convert 
the drugs to more polar compounds that can be readily excreted from the body. Interestingly 
when these enzymes metabolize drugs they can produce active or inactive metabolites. If the 
metabolites formed are inactive the dose of the drug that reaches the systemic circulation is 
reduced whereas if the metabolites formed are active then depending on the enzyme activity and 
the amount of active metabolite formed the efficacy of the drug will vary. CYP3A4 is said to 
metabolize almost 50% of the drugs currently present in the market and another 30% of drugs 
are metabolized by CYP2D6 (Zuber et al., 2002). 
 
“Reduction in hepatic blood flow and in hepatic sinusoidal endothelium with effects on drug 
transfer and oxygen delivery, reduce hepatic drug clearance” (McLean & Le Couteur, 2004). 
Reduced liver mass in aged patients may be responsible for the reduced clearance of many 
agents. There is a significant reduction in the clearance of many drugs metabolized by Phase I 
pathways in the liver. It remains unclear whether enzyme responsiveness changes with aging in 
humans. No major effects of aging in the pathways of conjugation were reported. 
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Differences in terms of pharmacodynamics and therapeutic drug response due to the influence of 
age and gender on the activity of hepatic and gastro intestinal CYP3A4 isoforms have yielded 
inconsistent results (Cotreau et al., 2005). Studies on the effect of age on triazolam, an exclusive 
CYP3A4 substrate, demonstrated significant decrease in weight-normalized clearance among 
healthy elderly subjects compared to young control subjects (Greenblatt et al., 1983; Greenblatt 
et al., 1991). Other reports state that the effect of age is not significant (Robin et al., 1996;. 
Smith et al., 1983). A study that involved S9 fractions from Sprague Dawley male rats of age 
groups 3-, 6-, 12- and 18-month old showed that the pharmacokinetic parameters (t1/2 and AUC) 
increased and drug clearance of ketamine-xylazine decreased with aging.  The findings for liver 
S9 fractions of 18-month-old rats compared with the other age groups suggested that following a 
normal ketamine anesthetic dose, drug metabolism was impaired, leading to significant increase 
of drug exposure (Giroux et al., 2013). 
I.7.4 Elimination 
 
Reduction in renal function in elderly patients affects many drugs such as water-soluble 
antibiotics (Lumholtz et al., 1974; Triggs et al., 1980), diuretics (Somogyi et al., 1990), digoxin 
(Portnoi, 1979), β-adrenoreceptor blockers (Rigby et al., 1985), lithium (Hewick et al., 1977) 
and NSAIDs (Oberbauer, 1993; Ritch, 1982) . Reduction of renal elimination is clinically 
important because it can lead to toxicity of drugs due to their accumulation in the body. 
I.8 Age-related changes on pharmacodynamics of drugs  
 
Biological aging processes are linked mechanistically to altered drug handling, altered 
physiological reserve and pharmacodynamics responses. Oral loading doses may require a 
reduction in account for age-related increase in bioavailability. Altered pharmacodynamics are 
well documented in the cardiovascular system, with changes in the autonomic system, autacoid 
receptors, drug receptors, and endothelial function to modify baseline cardiovascular tone and 
responses to stimuli such as postural change and feeding (McLean & Le Couteur, 2004). 
 
Older adults show an exaggerated response to CNS active drugs. It is in part due to an 
underlying decline in CNS function and increased pharmacodynamics sensitivity for some 
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benzodiazepine, anesthetic and opioid drugs (Bowie & Slattum, 2007). Shorter duration and a 
decreased depth of anesthesia with aging was reported in a study involving 3-, 6-, 12- and 18-
month old Sprague Dawley rats. Significant cardiac and respiratory depression, as well as 
decreased blood oxygen saturation, occurred in all age groups however, cardiac frequency was 
the most affected parameter with aging (Giroux et al., 2015). Data regarding the effect of age on 
opioid pharmacokinetics and pharmacodynamics are scarce and in some cases the results have 
shown conflicting conclusions. 
 
A decrease in renal weight and number of glomeruli in subjects older than 50 years due to aging 
process is observed. The basement membrane of the kidneys thickens and the number of 
schlerotic glomeruli increase. These changes occur due to normal aging but can be accelerated 
by onset of diseases (Muhlberg & Platt, 1999). Renal aging is evident through reduction in renal 
clearance in the elderly that is primarily disease-related. Pathophysiology plays an increasingly 
important role with age and thus may also affect the pharmacodynamics of drugs. Polypharmacy, 
the administration of various drugs to a single patient is common in the elderly and it increases 
the risk of drug interactions and side effects. Polypharmacy and adverse drug reactions represent 
major links to avoidable morbidity and mortality. 
 
A general trend of greater pharmacodynamics sensitivity is observed in the elderly however it is 
not universal and the age-related changes must be investigated agent by agent until further 
research yields greater understanding of the molecular mechanisms underlying the aging process. 
I.9 Effects on polymorphism and aging 
 
Pharmacokinetics and pharmacodynamics changes occur with increasing age. Several studies 
have shown a decrease in the metabolism of drugs by CYP450 with age. The clearance of 
theophylline by CYP1A2 was decreased with aging in humans (Jusko et al., 1979; Ohnishi et al., 
2003; Otero et al., 1996; Vestal et al., 1993). This has been interpreted as representing a decrease 
in CYP1A activity with aging (Schwartz, 2007).  
 
Limited data is available on age related changes on metabolism of CYP2C9 and CYP2C19 
substrates in humans, but the studies that have been performed shows age related decrease in 
clearance in the order of 25% and show slower clearance in women compared to men 
 38 
 
(Bachmann & Belloto, 1999). After a single intravenous dose, the effects of genotype and age 
were analyzed for omeprazole. CYP2C19 pharmacogenetic variants were significant covariates, 
for systemic clearance, the elderly extensive metabolizers showed wide variation in clearance 
and were phenotypically closer to the elderly poor metabolizers, than the young extensive 
metabolizers to the young poor metabolizers. The conclusion was CYP2C19 genotyping might 
not be as useful as phenotyping in the elderly (Ishizawa et al., 2005). 
 
Genetic polymorphism of CYP2D6 results in varying clearance ratios for its substrates in 
humans. Dextromethorphan metabolic ratios have been reported as slightly higher in older 
women than in middle aged women suggesting slower metabolism in elderly (O'Connell et al., 
2006). In healthy subjects with either extensive metabolizer phenotype or genotype, men have 
been reported to have faster clearance of dextromethorphan than women (Labbe et al., 2000; 
Tamminga et al., 1999). In Japanese men with extensive or intermediate metabolizer genotype, 
older age was also associated with slower haloperidol clearance (Ohara et al., 2003). Literature 
review on substrate clearance by CYP2D6 in humans suggests that older age is associated with 
slower clearance on the magnitude of 20% (Dorne et al., 2002), suggesting that doses of 
CYP2D6 substrates should be reduced by approximately 20% in the elderly (Schwartz, 2007).  
 
Rodent models have shown a consistent decrease in clearance of CYP3A substrate with aging 
(Santamaria R. et al. 2015,Cotreau et al., 2005; Patki et al., 2004; Schmucker, 2001) but this has 
not been observed in humans (Cotreau et al., 2005; Patki et al., 2004; Schmucker, 2001). In 
vitro, using human liver microsomes, earlier studies have shown no decrease in CYP3A activity 
or content with age (Parkinson et al., 2004; Schmucker et al., 1990). CYP3A activity and 
expression in non-alcoholic fatty liver disease were recently evaluated and it was observed that 
in vivo CYP3A activity was reduced (Woolsey et al., 2015). Liver fibrosis was associated with 
lower CYP3A enzyme function.  CYP3A mRNA expression in vivo was found to be reduced in 
non alcoholic fatty liver disease than in the normal healthy control subjects leading to a decrease 
in CYP3A activity (Woolsey et al., 2015).  
I.10 In vitro metabolism models 
 
The most effective approach to determine in vivo metabolism in humans is by in vitro screening 
using liver-derived experimental systems. Over the decades many in vitro liver models have 
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been developed and they include tests that use: primary hepatocytes, liver slices, perfused liver, 
cytosol, liver cell lines, transgenic liver cell lines, microsomes, liver S9 fractions, supersomes. 
 
With the exception of perfused liver, liver slices, and primary hepatocytes, all the in-vitro models 
require exogenous cofactors for their activities. The two exogenous factors used are NADPH 
(Nicotinamide adenine dinucleotide phosphate) system for Phase1 oxidation, essential for 
measurement of oxidase activity catalyzed by CYPP450 or uridine-5’-diphospho-alpha-D-
glucuronic acid (UDPGA) responsible for Phase II glucuronidation. 
I.10.1 Hepatocytes 
 
Hepatocytes are used to study both Phase I oxidation process and Phase II glucuronidation 
process in the liver (Li, 2005). They have an excellent in vivo-in vitro correlation. Their major 
disadvantage is that they lack non-hepatocyte cells and hence there is no cofactor supply. 
Furthermore there can be individual variations, which can be reduced by using hepatocyte pools 
from multiple donors (Brandon et al., 2003). Primary hepatocytes are used for metabolic stability 
studies, for identification of metabolites and their profiling, for drug-drug interactions and 
hepatotoxicity studies.  
I.10.2 Liver slices 
 
Liver slices are not available commercially (Brandon et al., 2003). They are normally used to 
study induction of CYP isoforms. Nutrient media cannot easily penetrate into the liver slices and 
hence CYPs have a very short viability of 5 hours, which is a disadvantage. 
I.10.3 Perfused liver 
 
Perfused liver can only come from animals and not from humans. The method is labour 
intensive, has poor reproducibility and its viability lasts only 3 hours (Brandon et al., 2003). It is 
only used when bile secretions are necessary for metabolic studies or when validation of another 
in vitro model is required. 
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I.10.4 Cytosol 
 
Cytosol is the aqueous part of the cytoplasm consisting of water, organic solvents and ions. 
Cytosol contains Phase II enzymes like glutathione S-transferase, N-acetyl transferase, and 
sulfotransferase. It is commercially available. The advantage of cytosol is that soluble Phase II 
enzyme metabolism can be investigated but enzymes like UGT (Uridine 5'-diphospho-
glucuronyltransferase) which are normally present on the endoplasmic reticulum (ER) cannot be 
investigated. 
I.10.5 Cell lines 
 
Cell lines are used only in enzyme induced states or in the study of cytotoxicity of drugs. In cell 
lines there is an incomplete expression of metabolic enzymes. Cell lines that are commercially 
available include Hep G2 from hepatocellular carcinoma, BC2 from hepatoma etc. Since cell 
lines have low expression or absence of Phase I and Phase II enzymes, they are not used for 
studies of CYPs metabolism (Asha & Vidyavathi, 2010). 
I.10.6 Transgenic cell lines 
 
Cell lines are transfected at high efficiency using centrifugation of lysozyme-treated bacteria 
bearing the desired vector with the parent cells in the presence of polyethylene glycol protoplast 
fusion (Brandon et al., 2003). Transgenic cell lines are very expensive and are generally used to 
form metabolites for structure elucidation. They have high expressions of CYPs and UGT and 
they can be used to study single enzyme reactions. They do not provide complete information of 
in vivo metabolism due to the presence of some isozymes. 
I.10.7 Microsomes 
 
These are prepared by homogenization of the liver followed by centrifugation of the subcellular 
fraction from ER of hepatic cells (Pelkonen et al., 1974). Microsomes are excellent for the study 
of Phase1 reactions. NADPH system is added to provide energy as a cofactor for the CYPs, 
otherwise UDPGA can be added for glucuronidation reactions. Microsomes are rich in CYPs, 
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carboxylesterase, flavin monoxygenase and a few other enzymes. The main advantages of 
microsomes include low cost, easy storage, possibility of gender study and possibility of 
studying inter individual variations. The disadvantages of microsomes include high 
concentration of CYPs and hence it does not resemble in vivo metabolism where the 
concentration of enzymes is lower, Phase II enzymes are absent and so are the cytosol enzymes, 
incubation of microsomes with different solvents, pH values and different chemicals can affect 
the metabolism and formed metabolites. There are inter-individual variations in the activity of 
human liver microsomes, but this problem can be overcome by the application of pooled 
microsomes (Araya & Wikvall, 1999). 
I.10.8 Liver S9 fractions 
 
S9 fractions have both microsomal and cystolic fractions of the liver and hence they are able to 
give complete profile of the metabolism that can occur in vivo in intact liver cells. NADPH 
system has to be added to supply CYPs with energy required by them to metabolize xenobiotics. 
Phase I and Phase II enzymes are all present and hence all metabolites formed by these enzymes 
can be studied. S9 fractions have lower expression of enzymes compared to cytosol and 
microsomes, hence some metabolites might go undetected. For the catalytic activity of phase II 
enzymes, addition of exogenous cofactors is necessary: UDPGA and alamethicin for UGT; 
acetyl CoA, DTT, and acetyl CoA regenerating system for N-acetyl transferase; adenosine-3-
phoaphate-5-phosphosulphate for sulfotransferase; and glutathione for glutathione-S-transferase 
(Brandon et al., 2003). A more complete representation of metabolic profile in the liver is 
offered by S9 in comparison to cytosol and microsomes. Metabolites formed by phase I reaction 
followed by Phase II reaction might not be formed in cytosol and microsomes but can be 
detected with S9 fractions. 
I.10.9 Supersomes 
 
Microsomes, which consist of vesicles of the hepatocyte endoplasmic reticulum of human CYP- 
or UGT-transfected insect cells are referred to as baculosomes or supersomes (Chen et al., 1997). 
Supersomes have specifically expressed human CYPs and UGTs. It allows the investigation of 
the contribution of a single metabolic enzyme to the biotransformation pathway of the compound 
under investigation. All common human CYPs, coexpressed with NADPH-cytochrome P450 
 42 
 
reductase and UGT are available in supersomes. The use of a regenerating NADPH-system is 
required to supply energy for UGT, thus uridine diphosphate glucuronic acid has to be added as 
cofactor. The advantages of supersomes include their use to study isozyme-specific drug 
transformation, drug to drug interactions, and the influence of polymorphism on the drug 
biotransformation pattern. The disadvantages in UGT supersomes are the UGT active site is 
shielded behind a hydrophobic barrier, which can be overcome by using a pore-forming agent 
(Fisher et al., 2001). 
I.11 Substrate depletion model 
 
The prediction of in vivo drug clearance from in vitro drug metabolite-kinetic data is well 
established in the rat. The metabolic rate-substrate concentration relationship can commonly be 
described by the classic hyperbola consistent with Michaelis-Menten model. A wide variety of 
drugs and other foreign compounds are metabolized by CYPs. The kinetic properties of these 
enzymes are often described satisfactorily by the classical Michaelis-Menten model: 
 
V = 
!"#$ ! !!" ! !          (1) 
 
V = velocity of the metabolic reaction, S = substrate concentration, Km = Michaelis Menten 
constant; when the rate of metabolism is 50% of Vmax. 
 
Michaelis-Menten model can be used for scaling in vitro kinetic data to predict the in vivo 
clearance of drugs (Houston, 1994). Therapeutic drug concentrations rarely approach the Km; the 
first order limit of equation (1) is applicable to describe the rate of metabolism in vivo. At very 
low substrate concentration, when [S] is much less than Km, equation (1) is formed, the rate is 
directly proportional to the substrate concentration.  
 !! = !"#$!" ! ! ≈ !"#$!"           (1) 
 
The determination of in vitro intrinsic clearance (CLint) for drug candidates in the early drug 
discovery stage is a common practice in the pharmaceutical industry (Houston,1994; Lave et al., 
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1997; Obach et al., 1997). The CLint values of drug candidates can help to confirm whether 
metabolism is the main clearance pathway when it is compared with the total body clearance in 
vivo. The in vitro CLint may be derived from enzyme kinetic data such as Vmax/Km (Lin et al., 
1996; Tan and Pang, 2001; Griffin and Houston, 2004) or from the in vitro t1/2 values where 
subKm substrate concentrations are used (Lave et al., 1997; Obach 1999; Lau et al., 2002; Jones 
and Houston, 2004). The ratio Vmax/Km, provides the parameter intrinsic clearance (CLint) which 
defines the rate of metabolism for a given drug concentration. 
 
CLint =  
!"#$!"           (2) 
 
An important parameter for CYP450-mediated drug biotransformation reaction is the Michaelis 
constant (Km). Enzyme kinetic parameters; Km, Vmax and CLint for CYP450 catalyzed reactions is 
an important aspect in drug discovery and development (Obach, 2001). These in vitro data can 
be used to optimize the human pharmacokinetic behavior of new chemical entities prior to 
human administration (Obach & Reed-Hagen, 2002). 
 
Km is an indicator of the affinity that an enzyme has for a particular substrate, hence the 
thermodynamic stability of the enzyme- substrate complex. The stability of the enzyme-substrate 
complex is closely related to the enzyme structure. It plays a central role in defining 
energetically favored binding cluster of the substrate in the active enzyme site (Lavoie et al., 
2013). Km value is a primary descriptor of enzyme kinetic behavior of biotransformation 
reaction. It represents the substrate concentration that will yield a reaction velocity that is half of 
the theoretical maximum velocity that would occur at an infinite substrate concentration (Vmax). 
In other words, the Km value tells us the potential of a drug to saturate or partially saturate an 
enzyme involved in its metabolic clearance. Lower Km values show a greater possibility that the 
drug concentration attained in vivo will saturate the metabolic clearance pathway. 
 
The rate of metabolite formation at several substrate concentrations can be assessed for the 
conventional determination of Km values. Substrate loss versus time using the in vitro t1/2 
approach gives overall intrinsic clearance estimates. It involves the measurement of substrate 
consumption at a single low concentration (<Km). This simple design yields an estimate of 
intrinsic clearance. 
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Km provides a measure of the substrate concentration required for significant catalysis to occur. 
Experimental evidence shows that Km for many enzymes provides an approximation of substrate 
concentration in vivo. Km is also related to the rate constant of the individual steps in the 
catalytic scheme:    
 
 
 
Km is defined as 
!!!!!!!!           (4) 
If K-1>>K2 the ES complex dissociates to E and S much more rapidly than the product is formed 
Km = 
!!!!!           (5) 
The dissociation complex is given by: 
 
KES = 
[!][!][!"]  = !!!!!           (6) 
 
Therefore Km is equal to the dissociation constant of the ES complex if k2<<k-1. In such cases, 
Km is a measure of the ES complex; a high Km indicates weak binding; a low Km indicates strong 
binding. Vmax indicates the turnover number of an enzyme, which is the number of substrate 
molecules converted into product by an enzyme molecule in a unit time when the enzyme is fully 
saturated with substrate. It is equal to the kinetic constant k2, also known as kcat. A decreased 
Vmax value suggests a rapid saturation of enzyme active sites that can be due to the formation of a 
more stable enzyme-substrate complex (ES), leading to a decrease of kcat and Vmax due to an 
increase in ΔG‡. 
 
kcat = 
!"#$[!"]           (7) 
I.12 Animal Cytochrome P450  
 
The use of animal models for preclinical drug development for the prediction of metabolic 
behaviour in humans requires a connection between the different isoforms of CYPs present in 
humans to animals. Pharmacokinetic data can be extrapolated from animals to humans 
k2 
k-1 
E + S k1 ES  E + P (3) 
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reasonably well applying appropriate pharmacokinetic principles. There is a relatively small 
difference in the primary amino acid sequences of CYPS across species since they possess a 
highly conserved region of amino acid residues. However, even small changes in the amino acid 
sequences can give rise to profound differences in substrate specificity and catalytic activity 
(Martignoni et al., 2006). Table shows the different CYP isoforms present in animals and 
humans. 
 
CYP2D6. In human CYP2D accounts for only 4% of the total CYPs present in the liver (Madani 
et al., 1999; Zuber et al., 2002) and only one isoform CYP2D6 is expressed whereas in rats six 
isoforms have been identified (Nelson et al., 1996). The rat and human CYP2D isoforms have a 
high sequence identity (>70%) (Venhorst et al., 2003). Among the six isoforms CYP2D1 is the 
rat orthologue of human CYP2D6 (Martignoni et al., 2006). Other studies state that rat CYP2D2 
is functionally conserved with human CYP2D in endogenous morphine formation (Grobe et al., 
2012). Like humans, polymorphism in rats has also been documented to provide models for PM 
and EM in humans (Al-Dabbagh et al., 1981). 
 
CYP3A. The content of CYP3A in the human liver accounts for only 30% of total CYPs present. 
Four isoforms of CYP3A are expressed in humans: CYP3A4, A5, A7 and A43. Of these 
CYP3A4 and CYP3A5 are the most abundant. In rats six isoforms have been reported that 
include CYP3A1, A2, A9, A18, A23 and A62. CYP3A2 in rats exhibits a 73% homology of the 
amino acid sequence and some substrate preference as well as functional analogies to human 
CYP3A4 (Martignoni et al., 2006). 
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Family Subfamily Human Mouse Rat Dog Monkey 
CYP1 A	 1A1, 1A2 1A1, 1A2 1A1, 1A2 1A1, 1A2 1A1, 1A2 
		 B	 1B1 1B1 1B1 1B1 1B1 
CYP2 A	 2A6, 2A7, 2A13 
2A4, 2A5, 
2A12, 2A22 2A1, 2A2, 2A3 2A13, 2A25 2A23, 2A2A 
		 B	 2B6, 2B7 2B9, 2B10 2B1, 2B2, 2B3 2B11 2B17 
		 C	
2C8, 2C9, 
2C18, 
2C19 
2C29, 2C37, 
2C38, 2C39, 
2C40, 2C44, 
2C50, 2C54, 
2C55 
2C6, 2C7, 2C11, 
2C12, 2C13, 
2C22, 2C23 
2C21, 2C41 2C20, 2C43 
		 D	 2D6, 2D7, 2D8 
2D9, 2D10, 
2D11, 2D12, 
2D13, 2D22, 
2D26, 2D34, 
2D40 
2D1, 2D2, 2D3, 
2D4, 2D5, 2D18 2D15 
2D17, 2D19, 
2D29, 2D30 
		 E	 2	E1	 2	E1	 2	E1	 2	E1	 2	E1	
CYP3 A	 3A4, 3A5, 3A7, 3A43 
3A11, 3A13, 
3A16, 3A25, 
3A41, 3A44 
3A1/A23, 3A2, 
3A9, 3A18, 
3A62 
3A12, 3A26 3A8 
Table 10: Major drug metabolizing CYP family of enxymes in humans, rat, mouse, dog and 
monkey. The isoforms in red represent the rat analogs to the human isoforms. Adapted from 
Martignoni et al., 2006. 
I.13 Common probe substrates 
 
The study of the metabolism of CYP450 enzymes by CYP probe substrates is well established in 
literature. Specific substrates for each subfamily of the CYP450 are well documented. The 
assesement of metabolic activity of various CYP enzymes is mostly assesed using selective 
substrates of distinct CYP enzymes that is a drug which is ideally metabolized by single CYP 
enzymes (Jurica et al. 2012). Pharmacokinetic of ideal marker should be determined by 
metabolism and not by intensity of liver perfusion, protein binding or elimination of unchanged 
drug. 
 
CYP2D6. Probe substrates for CYP2D6 are listed in Table 8. Among them dextromethorphan 
and debrisoquine are the most prefered for in vitro preclinical studies. The use of tramadol as a 
probe substrate is limited because in vitro studies show that the metabolite O-demethyltramadol 
is also mediated by CYP2B6 at a high extent. 
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CYP3A4. Common probes for CYP3A4 are listed in  Table 8. None of the suggested probes for 
CYP3A4 is metabolized uniquely by this enzyme and the active site is thought to be large and 
able to bind multiple substrates simultaneously, it is recommended to use at least two structurally 
unrelated probe substrates for precise enzyme activity evaluation (Jurica et al. 2012). 
 
Enzyme  Probe Substrate Enzyme  Probe Substrate 
CYP1A2 
Caffeine N-demethylation 
CYP2C19 
Chloroguanine  Conversion to cycloguanine 
Phenacetin O-deethylation Omeprazole  5-hydroxylation 
Theophylline N-demethylation S-mephenytoin 4’-hydroxylation 
CYP2C9 
Diclofenac 4’-hydroxylation 
CYP3A4 
Alfentanil Demethylation 
Losartan Oxidation Alprazolam 4-hydroxylation 
Phenytoin 4’-hydroxylation Codeine  O-demethylation 
S-flurbiprofen 4’-hydroxylation Cortisol 6-β hydroxylation 
S-warfarin 7-hydroxylation Dapsone N-hydroxylation 
Tolbutamide Methylhydroxylation Dextromethorphan  N-demethylation 
CYP2D6 
Codeine  O-demethylation Erythromycin N-demethylation 
Debrisoquine 4-hydroxylation Lidocaine N-deethylation 
Dextromethorphan O-demethylation Midazolam 1-hydroxylation 
Metoprolol α-hydroxylation Nifedipine Oxidation 
Sparteine Dehydrogenation Quinidine 3-hydroxylation/ N-oxidation 
Tramadol O-demethylation Testosterone 6-β hydroxylation 
Table 11: Probes for CYP450 metabolic activity assessment. Adapted from Jurica J and Sulcova 
A, 2012. 
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II Hypothesis and objectives  
 
CYP2D and CYP3A enzymes are involved in the metabolism of a large number of 
pharmaceutical drugs used in human and veterinary medicine. Nevertheless the effect of age on 
the metabolic function of this enzymes has not been extensively investigated. A large variation in 
the pharmacokinetic and pharmacodynamic response to codeine and oxycodone made us 
hypothesize that a decrease in the metabolic function of this enzyme, causing impaired 
metabolism of opioids leads to a decrease in the rate of formation of active metabolites and the 
accumulation of parent drug in the body.   
 
The objectives of this study were 
• To study the effect of age on CYP2D metabolic function. For this liver S9 fractions from 
3, 6, 12 and 18 month-old rats were used to perform in vitro metabolism of codeine and 
oxycodone. 
• To develop an HPLC-MS/MS method for the detection of codeine, oxycodone and their 
metabolites. An isotopic dilution method was used to quantify the rate of formation of 
metabolites by CYP2D and CYP3A at different age groups.  
• To perform metabolic stability studies of codeine and oxycodone. Michaelis-Menten 
equation was used to fit the data obtained and evaluate the impairment of CYP function 
with age using pharmacokinetic parameters. 
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Abstract 
 
Codeine and oxycodone are opioids used to alleviate pain. The outcome of the treatment is 
ultimately related to their metabolism by Cytochromes P450 (CYPs). Depending on the drugs 
used, alterations in the metabolism of drugs by CYPs can lead to severe consequences including 
alterations in their efficacy, safety and toxicity. The objectives of this study were to develop a 
novel HPLC-MS/MS method capable of quantifying codeine and oxycodone along with specific 
metabolites using an isotopic dilution strategy and study the rate of formation of morphine 
(CYP2D), norcodeine (CYP3A), oxymorphone (CYP2D) and noroxycodone (CYP3A). The 
chromatographic separation was achieved using a Biobasic C18 100 x 1 mm column combined 
with an isocratic mobile phase composed of methanol and 10 mM ammonium acetate (40:60) at 
a flow rate of 75 µL/min. The mass spectrometer was operating in scan mode MS/MS and the 
analytical range was set at 10–10 000 nM. The precision (%RSD) and accuracy (%RE) observed 
were 4.4–11.5 and -9.1–6.1% respectively. Liver S9 fractions from 3-, 6-, 12-, and 18-month-old 
male Sprague Dawley rats were prepared and Michaelis Menten parameters were determined. 
The derived maximum enzyme velocity (Vmax) suggested a rapid saturation of the CYP2D and 
CYP3A active sites in the liver S9 fractions of 18 month-old rats. Moreover, metabolic stability 
of codeine and oxycodone in rat liver S9 fractions were significantly greater for the 18-month-
old rats. This study suggests that there is an impairment of CYP2D and CYP3A metabolism in 
aging rats. 
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Introduction 
In recent years, the improvements in medicine, and changes in life style have increased life 
expectancy, and consequently there is a significant increase in geriatric patients needing medical 
and pharmacological treatments [Bunker., 2001]. A large proportion of marketed drugs have not 
been thoroughly tested in geriatric or pediatric patients and this has led to numerous medical 
complications [Richardson et al., 2014; Crentsil et al., 2014; Hines, 2013]. Older patients have 
higher risks of suffering from adverse drug effects which may be associated with a decreased 
drug clearance (CL) caused by physiologic changes associated with aging [Meziere et al., 2013; 
Woodhouse et al. 1988]. Additionally, other studies show a significant increase in terminal half-
life (T1/2) of many drugs related to aging [Iirola et al., 2012; Shi and Klotz, 2011] leading to 
important differences in pharmacokinetic profiles [Veilleux-Lemieux et al., 2013, Giroux et al., 
2016]. Alterations in pharmacokinetic and drug metabolism during aging have severe 
consequences particularly in pain management [Meziere et al., 2013]. The management of 
chronic pain in elderly patients is certainly not trivial and the efficacy of analgesics are 
inconsistent, resulting in a diminished quality of life for many patients.  
Opioids are important for the clinical management of pain, especially for cancer pain, surgical 
pain, and they are widely used for the management of chronic pain [Chau et al. 2008; Rosenblum 
et al. 2008]. Understanding the metabolism of opioids is therefore important for primary care 
clinicians. It is well established that the knowledge about opioid metabolism is essential for 
safety considerations in older and medically complicated patients, who might be taking multiple 
medications and suffer from inflammation as well as renal, hepatic and immune impairments. 
Interestingly, a large proportion of opioid drugs are primarily metabolized by CYP2D6 and 
CYP3A4 with the reported contribution of CYP2B6, CYP2C8, CYP2C9 and CYP2C19 [Smith. 
2009]. It is also important to understand that many opioid metabolites contribute significantly to 
their analgesic effects [Smith. 2009]. Therefore, understanding the fundamental mechanisms 
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influencing the metabolic fate of opioids is a necessary step for using them safely and efficiently 
in special population groups (i.e. pediatric and geriatric patients) [Zernikow B et al., 2009; 
Ginsburg et al., 2009].   
Codeine is used for mild to moderate pain treatment whereas oxycodone, which is twice as 
potent as morphine, is used to treat moderate to severe pain [Curtis GB et al. 1999; Waite I, 
2006]. Oxycodone has a lower renal clearance than codeine making it more suitable than 
morphine for geriatric patients [Ginsburg et al., 2009]. Both codeine and oxycodone exert their 
effects through µ-opioid receptors located in the central nervous system [Vallejo et al., 2011]. 
The metabolism of codeine and oxycodone is widely described in the scientific literature and 
both are substrates of CYP2D6 and CYP3A4 [Lalovic et al. 2004]. Codeine has no significant 
analgesic effect; it is only through its bioactivation by CYP2D6 leading to morphine that it can 
impart its analgesic effect [Poulsen L. et al. 1996]. An equivalent mechanism occurs in rats 
where codeine is converted to morphine by CYP2D1 [Martignoni et al. 2006, Cleary et al., 
1994]. Codeine is also a substrate for CYP3A4 forming norcodeine, an inactive metabolite. 
Lately, oxycodone has widely replaced morphine in the treatment of moderate to severe pain 
since it has a higher oral bioavailability when compared to morphine [Biancofiore, 2006]. In 
humans, oxycodone is metabolized by CYP2D6 and CYP3A4 to form oxymorphone and 
noroxycodone respectively [Löfdal  et al. 2013] but in rats it is metabolized by CYP2D1 and 
CYP3A2 [Cleary et al. 1994; Chan et al., 2008]. Oxycodone metabolites are active and 
contribute significantly to its analgesic effect [Lalovic et al. 2004]. Since the outcome of 
treatments by codeine and oxycodone are intimately related to drug metabolism, these two drugs 
can be used to systemically study the influence of aging on CYP3A and CYP2D mediated drug 
metabolism.  
A comprehensive understanding of the factors influencing drug metabolism are important for a 
safe and effective drug use in elderly patients. We therefore hypothesized that pharmacokinetic 
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alterations with aging can be largely due to drug metabolism impairment. We have recently 
generated pharmacokinetic and metabolism data on ketamine, a CYP3A substrate, to support this 
statement [Santamaria et al., 2015]. The rate of drug metabolism by CYPs is amenable to 
modulation by structural changes in the enzymes [Sheweita, 2000]. Additionally, enzyme 
modifications can have a significant impact on the formation and elimination of active 
metabolites and consequently have a profound effect on the pharmacological and toxicological 
outcomes. Our recent study showed a significant CYP3A metabolic impairment in older rats 
leading to decrease in drug clearance [Santamaria et al. 2015; Giroux et al. 2016]. In geriatric 
patients this could therefore lead to numerous medical complications.  
In the present study, functional changes will be characterized using two selective CYP2D and 
CYP3A substrates (i.e. codeine and oxycodone) and rat liver S9 fractions to define the metabolic 
stability and the enzyme-mediated clearance base on a Michaelis-Menten approach for specific 
metabolic pathways. Drug and metabolite analyses were performed using a HPLC-MS/MS 
method capable of quantifying codeine, norcodeine, morphine, oxycodone, oxymorphone and 
noroxycodone using an isotopic dilution strategy in liver S9 fraction suspensions. 
 
Materials and Methods 
 
 
Chemicals and Reagents 
 
Codeine, d3-Codeine, Norcodeine, d3-Morcodeine, Morphine, d3-Morphine, Oxycodone, d3-
Oxycodone, Noroxycodone, d3-Noroxycodone, Oxymorphone and d3-Oxymorphone were 
purchased from Cerilliant (Round Rock, TX). Other chemicals, including acetonitrile, formic 
acid, methanol, dibasic sodium phosphate and monobasic sodium phosphate, proteomic grade 
trypsin, dithiothreitol (DTT), iodoacetamide (IAA), hydrochloric acid (HCl), formic acid, LC-
MS grade water, LC-MS grade acetonitrile, hexane, trifluoroacetic acid (TFA) were purchased 
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from Fisher Scientific (Ottawa, ON, Canada). Commercial rat liver S9 fractions and NADPH 
regeneration solutions were purchased from Corning Gentest (Tewksbury, MA, USA).  
Animal study 
Twenty-four specific pathogen free male Sprague Dawley rats from Charles River Canada (St-
Constant, QC, Canada) were used for this study. Seven to nine weeks old rats (n=6/age group) 
were purchase and kept until they were respectively 3 and 6 months old. Twelve 8 month old rats 
were purchased and kept until they were 12 and 18 months of age (n=6/age group). All rats were 
housed in a standard laboratory animal environment. The rats had ad libidum access to food 
(2018 Teklad Global 18 % Protein Rodent Diet, Harlan Teklad, Bartonville, IL) and reverse 
osmosis water. They were single housed in ventilated cages (Green Line IVC Sealsafe Plus, 
Tecniplast, USA). Rats were housed on corn cob bedding (7097 corncob, Harlan Teklad, 
Bartonville, IL) which were changed once a week. They had a high temperature polycarbonate 
rat retreat (Bioserv, Flemington, NJ) and one Nylabone chew (Bioserv, Flemington, NJ) for 
environmental enrichment. The Institutional Animal Care and Use Committee of the Ste-Justine 
Hospital Research Center approved the protocol prior to animal use in agreement with the 
guidelines of the Canadian Council on Animal Care 1993. Rats were euthanized with CO2, livers 
were rapidly remove and S9 fractions were prepared. 
Rat Liver S9 preparation and incubation 
For each age group, three livers were pooled and homogenized in a 50 mM TRIS-HCl buffer, pH 
7.4, containing 150 mM KCl and 2 mM EDTA at a ratio of 1:4 (w:v). The homogenates were 
centrifuged at 9,000 g for 20 minutes. The total amount of protein in each supernatant was 
determined using the standard Coomassie protein assay (Bradford). Additionally, relative 
quantification of CYP2D and CYP3A was performed using a bottom-up proteomic strategy [C. 
Gröer et al. 2014] and results shown no statistical differences between age groups (data not 
shown). Supernatant aliquots were kept at -80 °C until usage. The incubations were performed as 
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previously described [Lavoie et al., 2013; Santamaria et al. 2014]. All incubations were 
performed minimally in triplicates. The incubations were performed in 1.5 mL microcentrifuge 
tubes and contained various concentrations ranging from 1 to 100 µM of codeine or 1 to 250 µM 
of oxycodone, 0.5 mg/mL of S9 fraction proteins diluted in 100 mM phosphate buffer, pH 7.4. 
One mL of S9 enzyme suspensions were fortified with 50 µL of NADPH-regenerating solution 
A and 10 µL of solution B (Corning BD Biosciences Cat. No. 451200) and preincubated at 37°C 
for 5 min prior to the addition of codeine or oxycodone. Immediately after fortification of 
codeine or oxycodone into the liver S9 suspension containing the NADPH-regeneration system, 
the sampling point for t = 0 was taken, and further sampling points were taken at 5, 15, 30, 45, 
60, and 90 min for metabolic stability experiments (i.e. substrate concentration was 2 µM). For 
the determination of Km and Vmax, the concentration of morphine, norcodeine, oxymorphone and 
noroxycodone were determined after 30 min incubation. Fifty µL of samples were taken and 
mixed with 250 µL of the deuterated internal standard solution (1 µM of deuterated internal 
standards in acetonitrile) in microcentrifuge tubes. The samples were centrifuged at 12,000 g for 
10 min and 200 µL of the supernatant was transferred into an injection vial for HPLC-MS/SRM 
analysis.   
Quantitative Analytical Methods 
 
The concentrations of codeine, morphine, norcodeine, oxycodone, oxymorphone and 
noroxycodone were determined using an HPLC-MS/SRM assay. Two µL samples were injected 
using a Thermo Scientific Accela HPLC System (San Jose, CA, USA) onto a Thermo Biobasic 
C18 100 x 1 mm column (5µm) with flow rate of 75 µL/min. The mobile phase consisted of a 
mixture of methanol, 10 mM ammonium acetate at a ratio of 40:60, respectively. The Thermo 
Scientific linear ion trap mass spectrometer (Thermo LTQ-XL) was interfaced with the HPLC 
system using a pneumatic assisted electrospray ion source. The mass spectrometer was coupled 
with the HPLC system using a pneumatically assisted electrospray ion source (ESI). The sheath 
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gas was set to 15 units and the ESI electrode was set to 4000 V in positive mode. The capillary 
temperature was set at 300 °C, the capillary voltage to 22 V.  Specific MS parameters are shown 
in Table 1. All scan events were acquired with a 100 msec maximum injection time. Drug, 
metabolites and corresponding deuterium-labeled molecule analogues were analyzed in scan 
mode MS/MS. The quantification was based on specific post-processing SRM extracted ion 
chromatograms and analyte concentrations were determined using the peak area ratio of the light 
and heavy analogs. The analytical range used was ranging from 10 nM to 10 000 nM for all 
analytes. The method precision and accuracy were evaluated by analyzing twelve replicates of 
liver S9 enzyme suspension samples fortified with codeine, morphine, norcodeine, oxycodone, 
oxymorphone, noroxycodone at the nominal concentration of 10, 500 and 10 000 nM. Please 
note that NADPH solution was added after the protein precipitation to avoid degradation.  
 
 
Data analysis and regression 
All non-linear regression analyses were performed with PRISM version 6.0h (GraphPad, La 
Jolla, CA) using the non-linear curve-fitting module with an estimation of the goodness of fit.  
The Michaelis-Menten equation describes the rates of irreversible enzymatic reactions that are 
generally observed for CYP mediated metabolic reactions. Michaelis-Menten parameters can be 
estimated with non-linear regression analysis using the Michaelis-Menten equation [Michaelis 
and Menten, 1913].  𝑣! = !!"# [!]!!! [!]  (1) 
Were the initial velocity (vi) was determined using equation 2. 𝑣! = ![!]!" = [!"#$%&'(]!" !"#!" !"#  𝑜𝑟 [!"#$%&$]!" !"#!" !"#  or [!"#$!%&!!"#]!" !"#!" !"#  𝑜𝑟 [!"#"$%&"'"!(]!" !"#!" !"#   (2) 
The initial rate (vi) was calculated based on the metabolite concentrations measured after 10 
minutes incubation of codeine or oxycodone in rat liver S9 enzyme suspensions. Following 
sample analysis, the analyte/deuterated internal standard peak area ratio was used to determine 
 57 
 
drug and metabolite concentrations at various time points to determine the metabolic stability. 
All depletion data were fitted to the monoexponential decay model described in equation (3) 
where C(t) are substrate concentration at time t and C0 is the initial concentration. 𝐶(𝑡) = 𝐶!𝑒!!"  (3) 
In vitro half-life was obtained using equation (4):  𝑇!/! = !"(!)!   (4) 
Statistical analysis 
Results are presented as means (± SD). The statistical difference was assessed with a one-way 
ANOVA and a Tukey's multiple comparisons test using PRISM software whereby; p < 0.05 was 
considered significant.  
Results and Discussion 
Tandem Mass Spectrometry 
Precursor ion and product ion mass spectra for codeine, morphine, norcodeine, oxycodone, 
oxymorphone, noroxycodone and deuterated analog internal standards were obtained in positive 
ion mode. The precursor ion spectra of codeine, norcodeine, morphine, oxycodone, 
oxymorphone, noroxycodone showed an intense signal for the protonated molecule ([M+H]+) at 
m/z 300, m/z 286, m/z 286, m/z 316, m/z 302 and m/z 302, respectively. Precursor ions detected 
for deuterated analogues were compatible with expected exact mass. The product ion spectra 
(MS2) of codeine, morphine, norcodeine, oxycodone, oxymorphone, noroxycodone has 
predominant fragment ions at m/z 215, m/z 201, m/z 215, m/z 256, m/z 242 and m/z 229 
respectively, as shown in Fig 2. As illustrated in Fig 3, the product ion spectra obtained were 
compatible with the molecular structures. The deuterated analog internal standards showed 
intense compatible fragment ions. The post acquisition SRM mass transition used are presented 
in Table 1 was set for best sensitivity and selectivity.  
 
 58 
 
Calibration Curve Analysis 
A linear regression (weighted 1/concentration) produced the best fit for the concentration–
detector relationship. The regression model used was determined using the sum of the squares of 
the deviations [Beaudry, 1999]. By convention, the regression line is considered to properly fit 
the calibration set when the sum of squares of the deviations is minimized. The calculated 
coefficient of determination (R2) were better than 0.990 for an analytical range set from 10 to 10 
000 nM in liver S9 enzyme suspensions.  
Precision and Accuracy 
The reproducibility of the method was evaluated by analyzing twelve replicates of liver S9 
enzyme suspension samples fortified with codeine, morphine, norcodeine, oxycodone, 
oxymorphone, noroxycodone at the nominal concentration of 10, 500 and 10 000 nM. The 
precision and accuracy results are displayed in Tables 2 and 3. The results obtained demonstrate 
that acceptable precision and accuracy results were achieved and were compatible with generally 
accepted criteria in bioanalysis (CDER and CVM, 2001). A representative chromatogram of 
LOQ samples is shown in Figure 4 and extracted blank rat liver S9 fraction did not show any 
interference from endogenous substances at the mass transition monitored for each analyte. 
Moreover, the signal-to-noise ratio of the LOQ sample was above 10:1 with a significant number 
of points to adequately determine peak area allowing the quantification of these analytes with 
acceptable figure of merits for a metabolism study.  
Determination of the apparent Michaelis constant Km and Vmax 
The rate of a specific metabolic pathway can be estimated using the Michaelis-Menten approach.  
The effect of substrate concentration on the initial rate (Vi) of an enzyme-catalyzed reaction is a 
central concept in enzyme kinetics. To adequately determine the value of the apparent Michaelis-
Menten constant Km as well as the maximum rate achieved by the system (Vmax), the data were 
fitted with the Michaelis-Menten equation (1). The initial rate (Vi) was calculated using the 
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equation (2) and concentrations of morphine (CYP2D), norcodeine (CYP3A), oxymorphone 
(CYP2D) and noroxycodone (CYP3A) were determined after 30 min codeine or oxycodone 
incubation in rat liver S9 fraction suspensions by HPLC-MS/MS.  Figures 5 and 6 show results 
coherent with kinetics following a Michaelis-Menten enzymatic reaction for all rat liver S9 
fractions from all age groups and data were compatible with commercial rat liver S9 fractions 
(data not shown). The derived data are presented in Table 4. Codeine is a well-characterized 
substrate of CYP2D and the primary biotransformation product is morphine, the active 
compound. The observed Km values were not significantly different when comparing age groups 
(Table 4 and Figure 5A). This is interesting because it suggests that with aging, the enzyme-
substrate complex structure was not significantly different between codeine and rat CYP2D (i.e. 
CYP2D1).  However, the derived Vmax suggests a rapid saturation of the CYP2D enzyme active 
sites in liver S9 fractions of 18-month-old rats, thus affecting significantly the enzyme-mediated 
clearance (CLuint = Vmax / Km) of the drug. Norcodeine formation mediated by CYP3A was also 
monitored, but the observed initial rate of formation was very low and did not allowed to 
adequately estimate Michaelis-Menten parameters. No significant formation of norcodeine using 
rat liver S9 fractions or commercial rat liver S9 fractions was observed in this study, particularly 
at low substrate concentrations. Thus, we could not accurately determine Km and Vmax. 
Oxycodone is a known substrate of CYP2D and CYP3A leading to two specific metabolites, 
oxymorphone and noroxycodone respectively. As shown in Table 4 and Figure 5B/5C, the 
observed Km values were not significantly different when comparing age groups despite some 
differences, which were noted (though not statistically significant) between 3-months-old rats 
compared with the other age groups. This observation is distinctive compared to rat liver CYP2D 
mediated metabolism of codeine. The Km value is directly related to the thermodynamic stability 
of the binding cluster of oxycodone in the active site of CYP2D or CYP3A. The data suggests 
differences showing a smaller Km values that may indicate that oxycodone may have stronger 
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interactions with CYP2D or CYP3A active site residues leading to more thermodynamically 
stable enzyme-substrate complexes. This may suggest drug metabolism changes with aging, a 
phenomenon observed in special populations groups like pediatric patients [Bartelink et al. 
2006]. The derived Vmax for CYP2D (oxymorphone) and CYP3A (noroxycodone) were 
compared and a rapid saturation of both enzyme active sites in liver S9 fractions of 18-month-old 
rats was observed, thus drastically affecting the enzyme-mediated clearance (CLuint) of 
oxycodone. The rates of formation of morphine, oxymorphone and noroxycodone undergo a 
very rapid saturation in the liver S9 fractions of 18-month-old rats suggesting that following a 
normal dose, drug metabolism can be impaired leading to a significant increase of drug 
exposition (AUC) and hampered elimination.  
Codeine and oxycodone metabolic stability evaluations in rat liver S9 fractions 
 
The in vitro metabolic stability (i.e T1/2) and enzyme-mediated clearance (Vmax / Km) were used 
to characterize functional modifications of CYP2D and CYP3A proteins with aging. The 
systemic drug exposition is intimately related with the metabolic stability. Codeine and 
oxycodone metabolic stability at 2 µM ([S] < Km) was evaluated in all age groups of rat liver S9 
fractions. The data presented in Figure 6A/6B were fitted with a mono-exponential decay model 
as described in equation (3) and the coefficients of determination (R2) were comprised between 
0.85 and 0.96 for each fitted data series, suggesting that codeine and oxycodone first-order 
kinetics were observed and the conditions of the model were met [Masimirembwa et al., 2001]. 
The derived T1/2 were significantly higher for experiments performed using 18-months-old liver 
S9 fractions compared to all other age groups (Table 4). These results are compatible with the 
enzyme-mediated clearances observed, and altogether suggest that systemic exposure will 
significantly increase with aging and drug clearance will be impaired leading to potentially 
undesired clinical outcomes.  
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Conclusion 
Age and related factors have a substantial effect on codeine and oxycodone bioavailability that 
are related to physiological changes but also biochemical changes such as liver metabolism 
alterations. The quantification of CYP2D and CYP3A enzyme levels reveals no statistical 
difference between age groups. Thus, significant decreases in the rate of formation of specific 
metabolites could be related to rat CYP2D and CYP3A conformational changes with age 
particularly in the geriatric group (18-month-old rats). More specifically, the results strongly 
suggest a severe impairment of CYP2D codeine metabolism as well as CYP2D and CYP3A 
oxycodone mediated metabolism.  Almost 50% of marketed drugs were metabolized by CYP3A 
and another 30% by CYP2D. Consequently, functional modifications of CYP enzymes can lead 
to severe consequences including alterations in efficacy, safety and toxicity of these drugs. 
Moreover, functional modifications of CYP enzymes may exacerbate problems associated with 
drug-drug interactions. Older patients under opioid treatments are most of the time considered 
medically complicated patients, whom might be taking multiple medications and may suffer 
from inflammation as well as renal and hepatic impairments. They are therefore more susceptible 
to potentially harmful drug-drug interactions. It is therefore essential to improve our 
understanding of the fundamental mechanisms associated with metabolic and pharmacological 
changes that occur with aging in order to develop predictive methods to aid the optimization of 
drug administration, to obtain the desired efficacy and to reduce or eliminate undesired clinical 
outcomes. 
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Table 1. Summary of compound specific parameters used for HPLC-MS/MS analysis.  
 
Compound	 Precursor	ion	
(m/z)	
Product	ion	
(m/z)	
Collision	Energy	
(%)	
Codeine	 300.2	 215.1	 45	
d3-Codeine	 303.2	 215.1	 45	
Morphine	 286.2	 201.1	 45	
d3-Morphine	 289.2	 201.1	 45	
Norcodeine	 286.2	 215.1	 40	
d3-Norcodeine	 289.2	 218.1	 40	
Oxycodone	 316.2	 256.1	 45	
d3-Oxycodone	 319.2	 259.1	 45	
Oxymorphone	 302.1	 242.1	 45	
d3-Oxymorphone	 305.1	 245.1	 45	
Noroxycodone	 302.1	 229.1	 40	
d3-Noroxycodone	 305.1	 232.1	 40	
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Table 2. Precision and accuracy evaluation for codeine and phase 1 metabolites in supernatant of 
Rat liver S9 fractions 
 
Compound	 Concentration	
(	nM	)	
Mean						
(n	=	12)	
RSD	(%)	 RE	(%)	
Codeine	
10	 9.36	 3.0	 -6.4	
500	 569.4	 2.6	 12.3	
10000	 9247.4	 2.7	 -7.5	
	 	 	 	 	
Morphine	
10	 9.62	 12.7	 -3.8	
500	 539.7	 2.7	 7.9	
10000	 9912.9	 3.4	 -0.9	
	 	 	 	 	
Norcodeine	
10	 10.99	 7.7	 9.9	
500	 532.8	 10.4	 6.6	
10000	 10030.2	 2.5	 0.3	
 
RSD = Relative Standard Deviation, RE = Relative Error 
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Table 3. Precision and accuracy evaluation for oxycodone and phase 1 metabolites in 
supernatant of rat liver S9 fractions 
 
Compound	 Concentration	
(	nM	)	
Mean							
(n	=	12)	
RSD	(%)	 RE	(%)	
Oxycodone	
10	 9.09	 4.4	 -9.1	
500	 462.9	 8.1	 -7.4	
10000	 9485.5	 5.0	 -5.1	
	 	 	 	 	
Oxymorphone	
10	 10.37	 8.0	 3.7	
500	 530.5	 11.5	 6.1	
10000	 9241.1	 6.1	 -7.6	
	 	 	 	 	
Noroxycodone	
10	 9.12	 6.4	 -8.8	
500	 504.6	 10.6	 0.9	
10000	 9194.5	 8.7	 -8.1	
 
RSD = Relative Standard Deviation, RE = Relative Error 
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Table 4. Kinetic parameters associated with the metabolism of Codeine and Oxycodone in 
rat liver S9 fractions  
	 Vmax	±	SD	
nmol	min-1	mg-1	
Km	±	SD	
µM	
(nmol	mL-1)	
T1/2	±	SD	
min	
Codeine	 	 	 	
3	months	
Morphine	(CYP2D)	
	
0.327	±	0.027	
	
10.3	±	3.4	
126.1	±	17.7	
6	months	
Morphine	(CYP2D)	
	
0.355	±	0.021	
	
9.0	±	2.2	
101.7	±	14.4	
12	months	
Morphine	(CYP2D)	
	
0.273	±	0.028a	
	
11.4	±	4.4		
162.6	±	32.8	
18	months	
Morphine	(CYP2D)	
	
0.092	±	0.003b	
	
10.9	±	1.2	
225.2	±	54.21	
	 	 	 	
Oxycodone	 	 	 	
3	months	
Oxymorphone	(CYP2D)	
Noroxycodone	(CYP3A)	
	
0.273	±	0.033c	
1.13	±	0.17c	
	
33.5	±	12.2	
47.6	±	19.4	
180.6	±	16.9	
6	months	
Oxymorphone	(CYP2D)	
Noroxycodone	(CYP3A)	
	
0.690	±	0.096	
2.92	±	0.47	
	
60.7	±	21.1	
61.1	±	24.7	
170.5	±	32.7	
12	months	
Oxymorphone	(CYP2D)	
Noroxycodone	(CYP3A)	
	
0.499	±	0.087d	
2.00	±	0.34d	
	
42.8	±	20.9	
49.5	±	22.5	
178.1	±	13.9	
18	months	
Oxymorphone	(CYP2D)	
Noroxycodone	(CYP3A)	
	
0.153	±	0.010e	
0.409	±	0.053e	
	
42.8	±	7.8	
40.6	±	14.8	
270.7	±	39.12	
 
a p < 0.01 compared to 6 months 
b p < 0.0001 compared to 3, 6 and 12 months 
c p < 0.001 compared to 6 months; p < 0.05 compared to 12 and 18 months 
d p < 0.05 compared to 6 months 
e p < 0.0001 compared to 6 and 12 months 
 
1 p < 0.05 compared to 3 months; p < 0.01 compared to 6 months 
2 p < 0.05 compared to 3 months and 12 months; p < 0.01 compared to 6 months 
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List of Figures 
Figure 1. Specific Phase 1 Liver CYPs mediated metabolism of codeine (A) and oxycodone (B) 
 
Figure 2. Product ion spectra (MS2) for codeine, oxycodone and their respective major CYPs 
metabolites. A) MS2 spectrum of codeine; B) MS2 spectrum of morphine; C) MS2 spectrum of 
norcodeine; D) MS2 spectrum of oxycodone; E) MS2 spectrum of oxymorphone; F) MS2 
spectrum of noroxycodone 
 
Figure 3. Proposed MS2 fragmentation mechanism. A) MS2 principal product ions for codeine; 
B) MS2 principal product ions for morphine; C) MS2 principal product ions for norcodeine; D) 
MS2 principal product ions for oxycodone; E) MS2 principal product ions for oxymorphone; F) 
MS2 principal product ions for noroxycodone 
 
Figure 4. Overlay reconstructed ion chromatograms of blank, LOQ and a reference samples for 
codeine, morphine, norcodeine, oxycodone, oxymorphone and noroxycodone. 
 
Figure 5. Determination of Michaelis constant Km and maximum velocity Vmax using non-linear 
regression fitting. The initial rate of formation (Vi) was measured for morphine (A), 
Oxymorphone (B) and Noroxycodone (C). Each point represents the mean (± SD) of 
experiments in triplicate. Significant differences of the initial rate of formation (Vi) where 
observed starting at 2 µM substrate concentration for liver S9 fractions of 18-month-old rats. 
 
Figure 6. Depletion profile of codeine (A) and oxycodone (B) in rat liver S9 fractions rat at 2 
µM. Data presented on a linear scale and each point represents the mean (±SD) of triplicate 
experiments. The half-life of both drugs is significantly increased in 18-month-old rat liver S9 
fraction. 
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Supplemental figure 
Legend 
Figure S1. Examples of calibration curves for each targeted analyte. Rat liver S9 fractions were 
fortified at six nominal concentrations and drugs and metabolites were extracted. Peak area ratios 
of drugs and metabolites and corresponding deuterium labeled analogs were used to construct the 
calibration curve. Deuterium labeled analogs were used at a constant concentration of 1 µM. The 
observed coefficient of determination (R2) was ≤ 0.99.  
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IV Discussion 
 
The evaluation of metabolism involved in the clearance of drugs is essential for the 
understanding of the cause of increased toxicity or decreased efficacy of drugs. In the literature, 
a decrease in clearance of drugs in geriatric patients has been reported (Mangoni & Jackson, 
2004)  and in common practise, the dose of drugs are generally decreased with age (Turnheim, 
2003). This decrease has been attributed to physiological changes like the decrease in blood 
flow, reduced liver mass, decreased renal weight and number of glomeruli in the kidneys but the 
specific mechanisms involved in the decrease of metabolism of drugs by the liver (Mangoni & 
Jackson, 2004) is still being further investigated.  
 
Opioids are an important class of drugs that are generally prescribed to reduce pain, but their 
toxicity can be severe. In clinical settings for elderly patients, opioids are generally titrated to 
reach an optimum dose and prevent the toxicity due to an overdose. Pharmacokinetic and 
pharmacodynamic studies regarding the effect of age on opioid clearance are scarce. Some of the 
existing theories include decreased liver perfusion, reduced liver mass and decreased lean body 
mass ratio. The CYP450 enzymes present in the liver are a major clearance pathway for a large 
percentage of pharmaceutical drugs currently prescribed in human and veterinary medicines. 
CYP2D and CYP3A are known to be responsible for the metabolism of a wide range of drugs 
including but not exclusive to analgesics, antidepressants and antipsychotics (Pinto & Dolan, 
2011). Impairment or hinderance of these enzymes could lead to severe drug toxicity or 
inefficacy due to the accumulation of  drugs in the the body.  
 
CYP2D is an important liver enzyme responsible for metabolising opioids. Pharmacogenetic 
differences have resulted in different phenotyping of humans into PM, IM, EM and UM. 
Codeine, a prodrug activated by this enzyme, has caused a large controversy where 
pharmacodynamic responses ranged from respiratory depression due to morphine toxicity and 
complete absence of analgesia. On a closer reexamination of the cases reported, toxicity due to 
morphine accumulation were always in children whereas the cases reporting absence of 
analgesia were at the geriatric age. The severe side effects of codeine enabled a clear observation 
of the trend of decreasing liver metabolism with aging in the clinical setting, but for other drugs 
that follow the CYP2D metabolism pathway, accumulation of the drugs causing only minor 
discomfort or milder side effects can leave them unnoticed. 
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Furthermore, a study of rectal codeine administration for post-operative analgesia in infants and 
children aged between 6 months and 4 years reported the mean initial half-life was 2.6 hours, but 
in the infants of the lower body weight, the half-life was over 2 hours longer (Quiding et al., 
1992). Another study reported that the plasma drug concentration indicated that a rectal dose of 
codeine of 0.5 mg/kg in children can result in similar, or slightly greater, plasma concentrations 
of codeine and its metabolites than after a 60 mg oral dose in adults (Quiding et al., 1986). 
Furthermore, a single-dose analysis of codeine offered no superior effect to placebo effect in 
adults following surgery or child birth (Honig & Murray, 1984). No significant advantage of 
codeine over placebo was observed in older patients with cancer pain but constipation as a side 
effect of codeine was observed (Jochimsen & Noyes, 1978). On the basis of available research 
findings, age specific differences in the pharmacokinetics of codeine may be significant 
(McEwan et al., 2000). In rodent model the evaluation of CYP3A substrate clearance have 
shown a consistent decrease with aging but this has not been observed in humans. No decrease in 
CYP3A activity or content with age was shown in human liver microsomes (Parkinson et al.., 
2004; Schmucker et al.., 1990). Recently, a reduced metabolism of ketamine in geriatric rats was 
reported (Santamaria R. et al., 2015.) 
 
Summary of results 
The experiments performed in this project were focused on the evaluation of CYP2D and 
CYP3A metabolic function with age using rat liver S9 fractions. Codeine and oxycodone were 
selected for use to evaluate the metabolic stability of CYP2D and CYP3A because they are well 
characterised substrates. The designed HPLC-MS method, allowed for selective quantification of 
codeine and its metabolites morphine and norcodeine and oxycodone and its metabolites 
noroxycodone and oxymorphone. The amount of noroxycodone could not be detected using the 
HPLC-MS method which might be due to low concentrations of the metabolite formed. The 
CYP2D and CYP3A content in relation to age, were quantified using bottom up proteomics 
(Groer et al., 2014). No significant difference in CYP2D and CYP3A content between different 
age groups were found. This is consistent with a previous publication (Schmucker et al., 1990) in 
which the authors reported that Phase I enzymes did not show change in CYP450 content with 
age.  
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The data generated by the HPLC-MS was fit into Michaelis-Menten equation. The presence of 
metabolites; morphine for codeine, oxymorphone and noroxycodone for oxycodone, were 
statistically compared between the different age groups. Results generated showed a clear 
decrease in the formation of morphine, oxymorphone and noroxycodone at the geriatric age. For 
codeine, the observed Km for morphine (CYP2D) values were not significantly different when 
comparing age groups. However, the derived Vmax suggests a rapid saturation of the CYP2D 
enzyme active site in 18-month old rats, thus affecting the enzyme mediated clearance of 
codeine. For oxycodone, the observed Km values for oxymorphone (CYP2D) and noroxycodone 
(CYP3A) showed no significant difference between different age groups but some differences, 
not statistically significant were noted which were not observed with codeine. These differences 
might be attributed to the thermodynamic stability of the binding cluster of oxycodone to the 
active site of CYP2D or CYP3A. The data suggests that oxycodone may have a stronger 
interaction with CYP2D than CYP3A active site residues leading to more thermodynamically 
stable enzyme-substrate complex. Surprisingly for oxymorphone and noroxycodone, low 
concentrations were seen at three month-old rats, but if the Km and Vmax values are used to 
evaluate the clearance between different age groups, we might observe that at three months, the 
low value of Vmax might be compensated with the Km value.  The results show a significant 
impairment in the metabolism of opioids by CYP2D and CYP3A in geriatric rats. 
 
 On a close observation, a pattern is seen where initially the metabolism by the two specified 
enzymes is low, it attains its maximum by middle age, then starts decreasing until finally it is 
impaired at the geriatric age. It is thus interpreted here that the enzymes develop till they attain 
enzymatic maturity and then start losing functionality after a certain age. This observation is 
consistent with the clinical cases reported in humans and the results obtained can be used to 
interpret the difference in pharmacodynamic response for different age groups observed in 
humans. 
 
The elimination half life was significantly higher for liver S9 fractions from the 18-month old 
rats compared to all other age groups for both codeine and oxycodone. The results were 
compatible with the observed enzyme-mediated clearance and when combined, it suggests that 
systemic exposure to codeine and oxycodone will significantly increase with age and drug 
clearance will be impaired leading to potential undesirable outcomes. 
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Relevance and Implications of observations  
According to the proposed hypothesis for the present study, the results clearly show impairment 
in CYP2D and CYP3A metabolism activity with age. This impairment could lead to the 
accumulation of drugs in the body. In the case of codeine, its accumulation could lead to side 
effects, such as itching, nausea, vomiting, coughing and constipation. Though they are not severe 
side effects, taking into consideration that codeine is often prescribed to geriatric patients to 
relieve mild to moderate pain, this will lead to absence of relief from pain in addition to the 
feeling of discomfort due to side effects. Elderly patients are also known to have bowel problems 
like constipation and codeine accumulation can worsen this in the elderly. Furthermore, pain that 
is not effectively treated may develop into chronic pain and hence elderly patients on codeine 
treatment may be at a higher risk of developing chronic pain. Even with the recent advancement 
in medicine, chronic pain still has no reliable treatment or cure and it is best to treat pain at its 
early stages before it develops into chronic pain. In the case of oxycodone, impairment of 
enzymatic clearance of the drugs could lead to severe side effects due to drug accumulation. The 
side effects of oxycodone include pinpoint pupils, constipation, nausea, vomiting, weak pulse, 
low blood pressure and respiratory depression leading to coma and death due to opioid overdose. 
 
The clinical observations related to codeine have led to the proposal of age altered metabolism. 
Earlier studies in humans for CYP1A activity showed a decrease with age (Schwartz, 2007). 
CYP3A impairment in geriatric rats has also been reported with other drugs (Cotreau et al., 
2005; Giroux M.C. et al., 2015; Patki et al., 2004; Schmucker, 2001; Santamaria R. et al. 2015). 
CYP2C9 and CYP2C19 showed a decrease in a clearance in the order of 25%, and that elderly 
extensive metabolizers were phenotypically closer to elderly poor metabolizers than the young 
extensive metabolizers  to the young poor metabolizers (Ishizawa et al., 2005). Combining the 
previous data with CYP2C9 and the data obtained for this experiment, an assumption that with 
age, extensive metabolizers might become poor metabolizers necessiating the need to decrease 
the dose of drugs metabolized by CYP2D and CYP3A in geriatric patients. Prodrugs that are 
activated by CYP2D and CYP3A enzymes might have to be revised to ensure patients are not 
being given drugs that are not activated, leading to aggrevations of their symptoms and the 
worsening of already existing diseases. 
 
Functional modification of CYP2D and CYP3A enzymes can lead to severe consequences 
including alterations in efficacy, safety and toxicity of drugs.  In elderly patients this is further 
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complicated by the presence of diseases like hepatic impairment and renal failure (Tajiri K. & 
Shimizu Y., 2013). Drug-drug interactions in this population due to polypharmacy also adds 
another problem to an already complex situation. The presence of drugs that can induce or 
inhibit CYP3A and CYP2D activity adds a new dimension to the complexity of the situation. 
The understanding of the exact mechanism associated with metabolic, psychological and 
pharmacological changes that occur with age is essential for the understanding, proper 
development and optimization of drug regimens in elderly patients. This will result in drug 
regimens that can produce the desired efficacy while reducing or eliminating undesirable side 
effects. 
 
CYP3A and CYP2D metabolism was found to be impaired in geriatric rats but comparing our 
findings with previously published data on CYP3A impairment in geriatric animals, that could 
not be interpreted into human, where a decrease in human CYP3A metabolism was not clinically 
observed, the results of this project will have to be carefully interpreted to clinical studies and 
further investigated. The impairment of CYP2D and CYP3A with age can be interpreted in terms 
of post translational modification in protein structure and misfolding, which can be correlated 
with an accumulation of oxidative stress damage. This will require further investigation through 
molecular modelling .  
 
Limitations  
Previous studies have shown that bacterial lipopolysaccharides induce the release of 
intermediary cytokines, which in turn induce  nitric oxide (NO) activity in Kupffer cells and 
hepatocytes (Khatsenko et al., 1993). NO is known to bind to both the ferric and the ferrous 
hemoproteins in intact CYP450 and prevents oxygen binding, thereby blocking enzyme activity. 
The capacity of NO to bind to CYP450 indicates that the decrease in total CYP450 could reflect 
masking of CO binding by NO resulting in the inactivation of CYP rather than a true decrease in 
CYP450 content. NO may also enhance degradation of CYP450 by nitrosylation of heme or 
thiols in CYP450 apoprotein or impair transcriptional activation of CYP450. NO-mediated 
suppression of CYP450 could have an important impact on the pharmacotherapy of patients who 
have infection or are undergoing cancer chemotherapy with cytokines (Khatsenko et al., 1993). 
 
It has also been reported that high fat diet alters intestinal microbial profile and increases 
intestinal permeability, leading to increased production and leaking of lipopolysaccharides (Zhao 
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& Chen, 2015). Lipopolysaccharides levels were also found to be elleviated in the circulation of 
aged humans. Obese patients have also been shown to have increased levels of 
lipopolysaccharides. Also results from one study show that an acute injection of 
lipopolysaccharides induce the gene expression of cytokines (Zhao & Chen, 2015). This 
information combined with the NO binding to CYP40 reducing its activity adds another 
limitation to this project which is the consideration of obesity and effect of aging on fat 
metabolism and lipopolysachaccarides. 
 
Finally,  recent studies have shown that non-alcoholic fatty liver diseases decrease in vivo 
CYP3A activity. Furthermore liver fibrosis was also associated with a decrease in CYP3A 
enzyme function. A reduction in the expression of CYP3A mRNA in vivo was reported in non- 
alcoholic fatty liver diseases when compared to healthy subjects (Woolsey et al., 2015). The 
effect of liver diseases on CYP2D and CYP3A function should also be taken into consideration 
to broaden our knowledge about the reasons for the impairment of these two enzymes in the 
geriatric age.  
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V Conclusion  
 
The in vitro experiments performed in the present study using rat liver S9 fractions from 
different age groups demonstrated that CYP2D and CYP3A metabolism are severely impaired 
with age. Since 50% of drugs are metabolized by CYP3A and another 30% by CYP2D the 
efficacy of drugs bioactivated by these two enzymes might decrease with age. This can lead to 
parent drug accumulation causing undesirable side effects without any drug efficacy. As for 
drugs that are metabolised to be cleared through CYP2D and CYP3A, the drugs might 
accumulate leading to toxicity due to high concentration of drug in the body. The accumulation 
of xenobiotics in the body is known to cause diseases such as organ failures, respiratory 
depression, coma which can ultimately lead to death. As such the dose of drugs metabolized by 
these enzymes might have to be decreased with age and optimization of drug has to be 
performed. In the case of CYP2D, phenotyping of patients might be more relevant at the geriatric 
age than genotyping as see in the case of CYP2C1. The use of codeine as a mild analgesic might 
be questionable since impaired CYP2D activity means diminished morphine formation. Previous  
studies have shown that PM suffered from side effects of codeine without experiencing any pain 
relief. 
 
Animals, especially dogs, are at a greater risk for developing harmful effects from the 
impairment of these two enzymes because of the presence of various races from the same species 
which makes it harder to predict the phenotype in each race. Polymorphism in different races of 
companion animals is not well studied and hence the effect of age on CYP2D for each race is 
hard to determine. This emphasizes the need to classify and study companion animals and their 
respective genotype and phenotype further for a better understanding of metabolism and to 
enhance the efficacy and decrease the toxicity of drugs being prescribed. Companion animals at 
geriatric age are known to suffer from similar diseases like geriatric humans including arthritis, 
diabetes and cancer. They are prescribed opioids for enhancement of the quality of life. Careful 
monitoring of opioids has to be done to prevent side effects and toxicity which is the result of 
impaired CYP2D and CYP3A metabolism. Cats are known to be deficient in Phase II 
metabolism, which can make geriatric cats more susceptible to the impairment of these enzymes 
since they lack an alternative pathway for the clearance of drugs.  
 
 85 
 
Although further studies are required to establish the exact mechanism by which CYP2D and 
CYP3A lose their functionality with age, the findings of our project suggest a severe impairment 
of metabolism which is a first step towards adjusting the doses of drugs in elderly patients 
including animals to enhance efficacy, maintain quality of life, decrease toxicity and prevent 
development of chronic pain. The results also highlight the importance of developing analgesics 
and other classes of drugs that are not metabolized by these enzymes to prevent complications in 
elderly patients. In addition to that, it clearly defines the importance of phenotyping rather than 
genotyping patients at different age groups for proper drug optimization. 
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VII Annex 
 
 
Figure 9: The content of CYP2D and CYP3A after bottom-up proteomics showed no statistical 
difference between different age groups when stastically compared using ANOVA and Tukey’s 
multiple comparison test. 
 
Bottom-up proteomics refers to the characterization of proteins by analysis of peptides released 
from the protein through proteolysis. It provides an indirect measurement of proteins through 
peptides derived from proteolytic digestion of intact proteins. The peptide is fractionated and 
subjected to LC-MS/MS analysis. In this study liver S9 fractions were digested with trypsin and 
analyzed with a high-resolution Orbitrap MS. 
 
